Original Article
Inhaled Iloprost for Severe Pulmonary Hypertension
N Engl J Med 2002; 347:322-329August 1, 2002
- Abstract
Background
Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension.
Methods
We compared repeated daily inhalations of 2.5 or 5.0 μg of iloprost (six or nine times per day; median inhaled dose, 30 μg per day) with inhalation of placebo. A total of 203 patients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (New York Heart Association [NYHA] functional class III or IV) were included. The primary end point was met if, after week 12, the NYHA class and distance walked in six minutes were improved by at least one class and at least 10 percent, respectively, in the absence of clinical deterioration according to predefined criteria and death.
Results
The combined clinical end point was met by 16.8 percent of the patients receiving iloprost, as compared with 4.9 percent of the patients receiving placebo (P=0.007). There were increases in the distance walked in six minutes of 36.4 m in the iloprost group as a whole (P=0.004) and of 58.8 m in the subgroup of patients with primary pulmonary hypertension. Overall, 4.0 percent of patients in the iloprost group (including one who died) and 13.7 percent of those in the placebo group (including four who died) did not complete the study (P=0.024); the most common reason for withdrawal was clinical deterioration. As compared with base-line values, hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation (P<0.001), were largely unchanged when measured before iloprost inhalation, and were significantly worse in the placebo group. Further significant beneficial effects of iloprost treatment included an improvement in the NYHA class (P=0.03), dyspnea (P=0.015), and quality of life (P=0.026). Syncope occurred with similar frequency in the two groups but was more frequently rated as serious in the iloprost group, although this adverse effect was not associated with clinical deterioration.
Conclusions
Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension.
Media in This Article
Figure 2
Kaplan–Meier Estimates of the Likelihood of Completing the 12-Week Study.Figure 1
Effect of Inhaled Iloprost and Placebo on the Mean (±SE) Change from Base Line in the Distance Walked in Six Minutes, According to an Intention-to-Treat Analysis.Article Activity
- Article
A continuous infusion of prostacyclin was the first therapy shown to reduce mortality in a controlled study of patients with severe pulmonary hypertension.1 However, its use is associated with a number of serious drawbacks. The lack of pulmonary selectivity results in systemic side effects, tolerance leads to progressive increases in the dose, and there may be recurrent infections of the intravenous catheter.2 As an alternative, inhaled nitric oxide possesses pulmonary selectivity, but it is less potent than prostacyclin in the pulmonary vasculature.3,4 Moreover, an interruption in the inhalation of continuous nitric oxide may cause rebound pulmonary hypertension.5,6 Designed to combine the beneficial effects of prostacyclin with those of an inhalational application, aerosolized prostacyclin was found to be a potent pulmonary vasodilator in patients with acute respiratory failure, exerting preferential vasodilatation in well-ventilated lung regions.7-10 Similar results were obtained in spontaneously breathing patients who had lung fibrosis and severe pulmonary hypertension.11
Iloprost is a stable analogue of prostacyclin that is associated with a longer duration of vasodilatation.12 When administered during a short aerosolization maneuver to patients with pulmonary hypertension, its pulmonary vasodilative potency was similar to that of prostacyclin, but its effects lasted for 30 to 90 minutes, as compared with 15 minutes.4,11,13-15 Several open-label, uncontrolled studies of patients with severe pulmonary hypertension suggested that long-term use of aerosolized iloprost results in substantial clinical improvement.11,13,16-20 Our objective in this trial was to evaluate the effects of inhaled iloprost using a rigorous end point of clinical efficacy.
Methods
Selection of Patients
Patients with primary pulmonary hypertension and selected forms of nonprimary pulmonary hypertension were candidates for the study. The forms of nonprimary pulmonary hypertension included appetite-suppressant–associated and scleroderma-associated pulmonary hypertension as well as inoperable chronic thromboembolic pulmonary hypertension. The inclusion criteria were a mean pulmonary-artery pressure greater than 30 mm Hg, the ability to cover between 50 and 500 m without encouragement on a six-minute walk test,21 and a New York Heart Association (NYHA) functional class of III or IV22 despite the use of standard conventional therapy (anticoagulants, diuretics, digitalis, calcium-channel blockers, and supplemental oxygen). Patients who were taking investigational drugs, prostanoids, or beta-blockers were excluded. The doses of calcium-channel blockers had to be constant for more than six weeks before study entry. Exclusion criteria were a pulmonary-artery wedge pressure at rest of more than 15 mm Hg, a cardiac index at rest of less than 1.5 or more than 4 liters per minute per square meter of body-surface area, bleeding disorders, a bilirubin level of more than 3 mg per deciliter (51 μmol per liter), creatinine clearance below 30 ml per minute, a forced vital capacity below 50 percent, a forced expiratory volume in one second that was less than the mean normal value minus twice the standard deviation, and clinical instability.
Study Design
A total of 203 patients participated after giving written informed consent and after the study had been approved by the local ethics committees at 37 European specialist centers. Patients were randomly assigned to receive iloprost (Ilomedin, Schering) or placebo after stratification according to NYHA functional class (III or IV) and type of pulmonary hypertension (primary or nonprimary) by an independent committee whose members were unaware of patients' identities. A total of 101 patients were randomly assigned to the iloprost group, and 102 were assigned to the placebo group.
For inhalation, iloprost or placebo was diluted with saline to a concentration of 10 μg per milliliter, and 2 ml was added to a nebulizer (HaloLite, MedicAid). This device delivered short pulses of aerosolized particles (geometric median [±SD] aerodynamic diameter of particles, 4.3±0.05 μm)23 during the first part of each inspiration until a predefined total inhaled dose of 2.5 μg had been dispensed. The inhalation was then stopped or repeated once, to achieve a total dose of 5.0 μg, depending on how well the patient tolerated the treatment. After each inhalation, the residual volume in the nebulizer was discarded. This maneuver was repeated six or nine times daily, with an overnight break. The frequency of inhalation and the dose were individually determined within the first eight days of therapy according to a predefined dosing algorithm.
Right-heart catheterization was performed in all patients at base line and after 12 weeks. The acute effects of inhaled iloprost were evaluated after 12 weeks in all patients, but not at base line, to avert unblinding. At base line and after 4, 8, and 12 weeks, patients completed a six-minute walk test, the Mahler Dyspnea Index questionnaire,24 the EuroQol questionnaire,25 and the 12-item Medical Outcomes Study Short-Form General Health Survey.26
Patients were removed from the study if they met two or more of the following predefined criteria for a deterioration in their condition: refractory systolic arterial hypotension (blood pressure, less than 85 mm Hg); worsening right ventricular failure (e.g., as indicated by the development of refractory edema or ascites); rapidly progressing cardiogenic, hepatic, or renal failure; a decrease of at least 30 percent in the distance walked in six minutes; and a decline in measures of hemodynamic function, such as central venous pressure and mixed venous oxygen saturation.
Outcome Measures
The primary end point of the study consisted of an increase of at least 10 percent in the distance walked in six minutes and an improvement in the NYHA functional class in the absence of a deterioration in the clinical condition or death during the 12 weeks of the study. Secondary efficacy variables were changes in the values for the six-minute walk test, the NYHA class, Mahler Dyspnea Index scores, hemodynamic variables, and the quality of life; clinical deterioration; death; and the need for transplantation.
Statistical Analysis
The primary evaluation of efficacy included all randomized patients. Data are presented as means ±SD, unless otherwise stated. We included data on patients who prematurely discontinued the study using a last-observation-carried-forward analysis for the six-minute walk test. Patients who died were assigned a value of 0 m. All statistical tests for efficacy variables were two-tailed, with an alpha level of 0.05.
To analyze the primary efficacy end point and the improvement criteria, we used the Mantel–Haenszel test,27 stratified according to the type of pulmonary hypertension (primary or nonprimary) and NYHA class (III or IV). Patients with missing data on the primary end point at week 12 were considered not to have had a response.
Changes in the results of the six-minute walk were evaluated with use of nonparametric analysis of covariance stratified according to the type of pulmonary hypertension (primary or nonprimary) and the NYHA class (III or IV), with use of the base-line value as the covariate (analysis of covariance), and the Wilcoxon signed-rank test.
Changes from base line in hemodynamic values were analyzed with t-statistics. The investigators had full access to the data and performed the analyses independently of the sponsor.
Results
Base-line demographic and hemodynamic data are given in Table 1Table 1
Base-Line Characteristics of the Patients.. The mean frequency of inhalation was 7.5 times per day. Ninety-one percent of patients received 5.0 μg per inhalation, and 9 percent received 2.5 μg, corresponding to a median inhaled dose of 30 μg per day.Primary Efficacy End Point
For the primary end point, we found a significant effect of treatment in favor of iloprost (P=0.007) (Figure 1Figure 1
Effect of Inhaled Iloprost and Placebo on the Mean (±SE) Change from Base Line in the Distance Walked in Six Minutes, According to an Intention-to-Treat Analysis.). The estimated odds of an effect in the iloprost group, as compared with the placebo group, were 3.97 (95 percent confidence interval, 1.47 to 10.75, by the Mantel–Haenszel test), with no significant heterogeneity among the four subgroups categorized according to type of pulmonary hypertension and NYHA class at base line (P=0.79 by the Breslow–Day test). The secondary analysis of the primary end point was a logistic-regression model that included treatment assignment, demographic data, and base-line characteristics. Only treatment assignment (P=0.01) contributed significantly to the probability of a response.Secondary End Points
Six-Minute Walk Test
The percentage of patients who had an increase of at least 10 percent in the distance walked in six minutes at week 12 was slightly, but not significantly, higher in the iloprost group than in the placebo group (P=0.06) (Table 2Table 2
Effects of 12 Weeks of Therapy with Inhaled Iloprost or Placebo on the New York Heart Association (NYHA) Class and the Six-Minute Walk Test.). The type of pulmonary hypertension had no significant effect on the outcome in either group (P=0.90). A higher percentage of patients in the placebo group than in the iloprost group had a decrease in the distance walked of at least 10 percent or did not complete the study (Table 2).The absolute change in the distance walked in six minutes was significantly larger (by 36.4 m) in the iloprost group than in the placebo group (P=0.004) (Figure 1): 58.8 m among those with primary pulmonary hypertension and 12 m among those with nonprimary pulmonary hypertension. A parametric analysis of covariance, which included the absolute value on the six-minute walk test at week 12 as a dependent variable and the treatment assignment (P=0.02), type of pulmonary hypertension (P=0.06), and distance walked at base line (P<0.001) did not show a statistically significant interaction between treatment and type of pulmonary hypertension (P=0.09).
NYHA Class
More patients in the iloprost group than in the placebo group had an improvement in the severity of heart failure, as assessed by the NYHA class (P=0.03) (Table 2). The type of pulmonary hypertension had no effect on the outcome in either group (P=0.39). The percentage of patients with a deterioration in NYHA class did not differ significantly between the groups, but the analysis did not include patients who left the study early owing to death or other reasons. A larger proportion of patients in the placebo group than in the iloprost group did not complete the study (Table 2 and Figure 2Figure 2
Kaplan–Meier Estimates of the Likelihood of Completing the 12-Week Study.). Reasons included death, discontinuation of study medication, and withdrawal of consent, mostly owing to clinical deterioration, insufficient clinical benefit, or both.Hemodynamics and Gas Exchange
In the placebo group, cardiac output, systemic arterial oxygen saturation, and mixed venous oxygen saturation decreased significantly after 12 weeks and pulmonary vascular resistance and right atrial pressure increased significantly (Table 3Table 3
Mean (±SD) Change from Base Line in Hemodynamic Values during 12 Weeks of Therapy with Inhaled Iloprost or Placebo.). In the iloprost group, values assessed at 12 weeks, before the first morning dose of inhaled iloprost, were largely unchanged from base line, whereas values assessed after inhalation were significantly decreased (in the case of pulmonary-artery pressure, pulmonary vascular resistance, systemic arterial pressure, and systemic arterial oxygen saturation) or increased (in the case of carbon monoxide and pulmonary-artery wedge pressure). At the completion of the 12-week study, acute hemodynamic responsiveness to inhaled iloprost was equivalent in the placebo group and the iloprost group, though the latter group had been exposed to daily iloprost inhalation for three months (data not shown).Mahler Dyspnea Index
The mean Mahler Dyspnea Index transition score was significantly better at week 12 in the iloprost group than in the placebo group (change, +1.42±2.59 vs. +0.30±2.45; P=0.015). The type of pulmonary hypertension had no effect on this outcome.
Quality of Life
Mean scores on the EuroQol visual-analogue scale improved significantly (from 46.9±15.9 to 52.8±19.1) in the iloprost group but were virtually unchanged in the placebo group (dropping from 48.6±16.9 to 47.4±21.1, P=0.026 by analysis of covariance). The EuroQol health-state score improved from 0.49±0.28 to 0.58±0.27 in the iloprost group and was unchanged in the placebo group (0.56±0.29 to 0.56±0.31, P=0.11 by analysis of covariance). None of the other measures of the quality of life were significantly different between the groups.
Clinical Deterioration and Death
One patient died in the iloprost group during the 12-week study, as compared with four patients in the placebo group (P=0.37) (Table 2). Criteria for clinical deterioration were met in 4.9 percent of patients in the iloprost group and 8.8 percent of those in the placebo group (P=0.41). This indicated that fewer patients either died or deteriorated in the iloprost group than in the placebo group (4.9 percent vs. 11.8 percent, P=0.09). The type of pulmonary hypertension had no effect on the outcome. During the study period, none of the patients received a lung transplant.
Safety
The total number of patients who had serious adverse events did not differ significantly between the groups (Table 4Table 4
Incidence of Serious and Other Adverse Events.). Right ventricular failure and edema were more than twice as frequent in the placebo group as in the iloprost group. The total number of syncopal events in each of the two groups was similar (eight in the iloprost group and five in the placebo group), but these events were more often considered serious in the iloprost group. Syncope was not associated with clinical deterioration or premature withdrawal from the study. Syncopal events occurred more than two hours after the last inhalation (often after an overnight break), were exercise-induced in two patients, were induced by bradycardia in two patients (associated with gastroenteritis in one patient and with verapamil therapy in the other), and resulted in head trauma in one patient. Flushing and jaw pain were more common in the iloprost group, but these adverse effects were mostly transient and mild and were not considered to be serious in any patient.Discussion
The results of this clinical trial demonstrate that long-term inhaled administration of aerosolized iloprost, a stable analogue of prostacyclin, improves a clinically important combined end point consisting of exercise capacity, NYHA class, and clinical deterioration in patients with selected forms of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Moreover, iloprost improved several secondary end points.
Since intravenous epoprostenol was shown to improve survival among the most severely ill patients with primary pulmonary hypertension, it has been unethical to perform randomized clinical trials among patients with pulmonary hypertension in which survival is used as an end point. We chose a combined rather than a single end point (e.g., the distance walked in six minutes) in order to make a more rigorous determination of whether inhaled iloprost was efficacious. Nearly 40 percent of all patients who were treated with iloprost increased their six-minute walking distance by at least 10 percent. However, only half as many patients also had improvement in the NYHA class; conversely, not all patients with an improvement in NYHA class had an increase of at least 10 percent in the distance walked in six minutes. Thus, although only 17 percent of patients in the iloprost group reached the combined end point, a substantial number of the remaining patients met less strict criteria for clinical improvement that would warrant continued therapy. Furthermore, significantly fewer patients in the iloprost group than in the placebo group prematurely discontinued the study as a result of lack of efficacy or other reasons, suggesting that even when iloprost therapy does not produce substantial improvement, it may stabilize the clinical condition.
The mean inhaled dose of iloprost corresponded to 0.37 ng per kilogram of body weight per minute, which is considerably lower than an effective intravenous or subcutaneous dose.2,28 Thus, targeted delivery of prostanoids to the pulmonary vasculature by means of inhalation may substantially reduce the drug requirements.
Like other investigators, we found that the benefit was greatest among patients with primary pulmonary hypertension and was similar to that of epoprostenol1 and bosentan.29 Although patients with nonprimary pulmonary hypertension had improvement in the scores for the Mahler Dyspnea Index and quality-of-life measures that were similar to those achieved in patients with primary pulmonary hypertension, fewer such patients reached the combined end point, and they also had a smaller absolute change in the distance walked in six minutes. Similar results have been obtained with the use of other drugs for pulmonary hypertension, including epoprostenol,30 beraprost,31 and treprostinil.28
Hemodynamic assessments of preinhalation values showed that values stabilized in the iloprost group, whereas they deteriorated in the placebo group. The degree of deterioration may be underestimated, since patients who discontinued treatment prematurely did not undergo follow-up hemodynamic examination. Postinhalation assessments of hemodynamic variables demonstrated a significant improvement in the iloprost group, as was anticipated on the basis of previous reports.4,11,13,16 Since the acute hemodynamic response did not differ between the groups, it appears unlikely that tolerance developed over the 12-week course of iloprost treatment. During long-term treatment, the patients' hemodynamic status is somewhere between preinhalation and postinhalation values. In comparison, continuous intravenous therapy may result in a more sustained hemodynamic improvement32; however, continuous intravenous therapy also poses considerable risks, including relapse after the interruption of therapy and complications, and is difficult to administer.
With respect to adverse events, flushing was more common in the iloprost group, but the frequency of most of the other inhalation-associated side effects was similar. There were more syncopal episodes in the iloprost group than in the placebo group (eight vs. five), and these episodes were more frequently defined as serious adverse events, but they were not associated with clinical deterioration. Since syncope occurred a relatively long time (two to nine hours) after the last inhalation, the loss of an effect of iloprost may have caused these events. However, the same side effect was observed with bosentan therapy, suggesting that these drugs may have a more pronounced effect on blood pressure during exercise. Alternatively, patients who had clinical improvement with therapy may have become more physically active, challenging the limits of their cardiac reserve. We would advise patients to increase their physical activity gradually after the initiation of therapy for pulmonary hypertension.
The inhalation device that we used provided accurate doses of iloprost. However, it is not battery-driven, and inhalation commonly required 10 minutes. Different techniques of administering aerosolized iloprost result in similar acute hemodynamic effects as long as identical doses are delivered to the respiratory tract in a particle size suitable for alveolar deposition.14,33 With other techniques, the duration of inhalation may be shortened considerably.14
In conclusion, this large, placebo-controlled trial demonstrates the efficacy and safety of inhaled iloprost for the treatment of severe primary pulmonary hypertension and selected forms of pulmonary arterial and chronic thromboembolic pulmonary hypertension. The advantages of intermittent inhaled therapy over intravenous therapy, coupled with the improvement in a number of clinically meaningful variables, suggest that inhaled iloprost therapy is effective. It may be a suitable alternative to continuous intravenous prostacyclin, especially in patients who do not derive a clear survival benefit with intravenous therapy.
Supported by Schering, Berlin, Germany. All the authors have financial relationships with Schering, the sponsor of the study. The relationships differ among the authors and include employment, consultancy, membership in the scientific advisory board, and support for work as investigators.
Source Information
From the Department of Internal Medicine II, University Clinic, Giessen, Germany (H.O., H.A.G., W.S.); Service de Pneumologie, Hôpital Antoine Béclère, Clamart, France (G.S., O.S.); Istituto di Cardiologia, Università di Bologna, Bologna, Italy (N.G., A.M.); Royal Hallamshire Hospital, Sheffield, United Kingdom (T.H., D.G.K.); Department of Cardiology, Erasme University Hospital, Brussels, Belgium (R.N.); University of California at San Diego Medical Center, La Jolla (L.J.R.); Schering, Berlin, Germany (S.N., H.S.); Department of Internal Medicine, University Hospital, Zurich, Switzerland (R.S., W.P.); Department of Pneumology, Hannover Medical School, Hannover, Germany (M.M.H.); the Division of Pulmonary Diseases, University of Munich–Großhadern, Munich, Germany (J.B.); Department of Pneumology, University Clinic, Leipzig, Germany (J.W.); Department of Pneumology and Infectious Diseases, Ernst Moritz Arndt University, Greisswald, Germany (R.E.); Bereich Pneumologie, Medizinische Kernklinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (A.M.); Freeman Hospital, High Heaton, Newcastle-upon-Tyne, United Kingdom (P.A.C.); Department of Pneumology, Gasthuisberg University Clinic, Leuven, Belgium (M.D.); and Pulmonary Hypertension Unit, Hospital 12 de Octubre, Madrid (M.G.-S.).
Address reprint requests to Dr. Seeger at the Department of Internal Medicine II, University Clinic, Klinikstr. 36, D-35392 Giessen, Germany, or at werner.seeger@innere.med.uni-giessen.de.
The other members of the Aerosolized Iloprost Randomized (AIR) study group are listed in the Appendix.
Appendix
The members of the AIR study group were as follows: Steering Committee — W. Seeger (chair), N. Galiè, T. Higenbottam, S. Nikkho, R. Naeije, H. Olschewski, L.J. Rubin, G. Simonneau; Other Investigators — H. Fabel and E. Spiekerkötter (Medizinische Hochschule, Hannover, Germany); F. Grimminger and R. Wiedemann (University Clinic, Giessen, Germany); H. Leuchte (University Clinic Großhadern, Munich, Germany); M. Aquilina (Università di Bologna, Bologna, Italy); K. Amsha and R. Lawson (Royal Hallamshire Hospital, Sheffield, United Kingdom); R. Alcock (Freeman Hospital, Newcastle-upon-Tyne, United Kingdom); A. Pforte (Universitätsklinik Eppendorf, Hamburg, Germany); J. Schauer (Medizinische Klinik und Poliklinik Universitätsklinik, Leipzig, Germany); W. Budts (Gasthuisberg University Clinic, Leuven, Belgium); P. Escribano and M. Lázaro (Hospital 12 de Octubre, Madrid); E. Huchalla (Hôpital Claude-Huriez, Lille, France); M. Borst (Ludolf-Krehl-Klinik, Heidelberg, Germany); C.M. Black (Royal Free Hospital, London); C. Bravo, A. Román, and V. Monforte (Centro Sanitario, Vall d'Hebron, Barcelona, Spain); A. Peacock (West Infirmary, Glasgow, United Kingdom); A. Boonstra (Academic Hospital, Free University, Amsterdam); C. Fracchia (Fondazione Salvatore Maugeri, Montescano, Italy); C. Marini (Istituto di Fisiologia Clinica Consiglio Nazionale della Ricerche, Pisa, Italy); L. Nicod (Hôpital Cantonal Universitaire, Geneva); J. Pepke-Zaba (Papworth Hospital, Cambridge University, Cambridge, United Kingdom); G. Sybrecht and H. Wilkens (Pneumologie Uniklinik, Homburg, Germany); A. Torbicki (National Institute of Tuberculosis and Lung Disease, Warsaw, Poland); P. Diot (Hôpital Bretonneau, Tours, France); T. Mota (Hospital de Pulido Valente, Lisbon, Portugal); J.L. Pennaforte (Centre Hospitalier Universitaire [CHU] Reims, Reims, France); T. Perez and F. Radenne (CHU Lille, Lille, France); C. Pison (CHU Hôpital Nord, Grenoble, France); J.L. Vachiery (Hôpital Erasme, Brussels, Belgium); P. Hallgren (Kardiologkliniken, Goteborg, Sweden); F.-X. Kleber (Unfallkrankenhaus, Berlin, Germany); L. Providencia (Hospitais de Universidade de Coimbra, Coimbra, Portugal); V.R.G. Ribeiro (Vila Nova de Caia, Portugal); M. Soler (Kantonsspital, Basel, Switzerland); and H. Stricker (Ospedale Regionale di Locarno La Caritá, Locarno, Switzerland).
- References
References
1
Barst RJ ,Rubin LJ ,Long WA , et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301
Full Text | Web of Science | Medline2
Barst RJ ,Rubin LJ ,McGoon MD ,Caldwell EJ ,Long WA ,Levy PS . Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415
Web of Science | Medline3
Warren JB ,Higenbottam T . Caution with use of inhaled nitric oxide. Lancet 1996;348:629-630
CrossRef | Web of Science | Medline4
Hoeper MM ,Olschewski H ,Ghofrani HA , et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176-182
CrossRef | Web of Science | Medline5
Miller OI ,Tang SF ,Keech A ,Celermajer DS . Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995;346:51-52
CrossRef | Web of Science | Medline6
Cueto E ,Lopez-Herce J ,Sanchez A ,Carrillo A . Life-threatening effects on discontinuing inhaled nitric oxide in children. Acta Paediatr 1997;86:1337-1339
CrossRef | Web of Science | Medline7
Walmrath D ,Schneider T ,Pilch J ,Grimminger F ,Seeger W . Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet 1993;342:961-962
CrossRef | Web of Science | Medline8
Walmrath D ,Schneider T ,Pilch J ,Schermuly R ,Grimminger F ,Seeger W . Effects of aerosolized prostacyclin in severe pneumonia: impact of fibrosis. Am J Respir Crit Care Med 1995;151:724-730
Web of Science | Medline9
Walmrath D ,Schneider T ,Schermuly R ,Olschewski H ,Grimminger F ,Seeger W . Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:991-996
Web of Science | Medline10
Zwissler B ,Kemming G ,Habler O , et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:1671-1677
Web of Science | Medline11
Olschewski H ,Ghofrani HA ,Walmrath D , et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-607
Web of Science | Medline12
Fitscha P ,Tiso B ,Krais T ,Sinzinger H . Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD). Adv Prostaglandin Thromboxane Leukot Res 1987;17:450-45413
Olschewski H ,Walmrath D ,Schermuly R ,Ghofrani HA ,Grimminger F ,Seeger W . Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-824
Web of Science | Medline14
Gessler T ,Schmehl T ,Hoeper MM , et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001;17:14-19
CrossRef | Web of Science | Medline15
Wensel R ,Opitz CF ,Ewert R ,Bruch L ,Kleber FX . Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000;101:2388-2392
Web of Science | Medline16
Hoeper MM ,Schwarze M ,Ehlerding S , et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-1870
Full Text | Web of Science | Medline17
Olschewski H ,Ghofrani HA ,Walmrath D ,Temmesfeld-Wollbruck B ,Grimminger F ,Seeger W . Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998;24:631-634
CrossRef | Web of Science | Medline18
Stricker H ,Domenighetti G ,Fiori G ,Mombelli G . Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Schweiz Med Wochenschr 1999;129:923-927
Medline19
Olschewski H ,Ghofrani HA ,Schmehl T , et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med 2000;132:435-443
Web of Science | Medline20
Beghetti M ,Berner M ,Rimensberger PC . Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001;86:E10-E10
CrossRef | Medline21
Guyatt GH ,Sullivan MJ ,Thompson PJ , et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923
Web of Science | Medline22
Rich S, ed. Primary pulmonary hypertension: executive summary from the World Symposium — Primary Pulmonary Hypertension 1998. Evian, France: World Health Organization, 1998. (Accessed July 8, 2002, at http://www.who.int/ncd/cvd/pph.html.)
23
Roth C ,Heyder J ,Wagner T ,Schmehl T ,Gessler T . In vitro characterization of Ilomedin inhalation devices. J Aerosol Med 1999;12:98-98 abstract.24
Mahler DA ,Weinberg DH ,Wells CK ,Feinstein AR . The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758
CrossRef | Web of Science | Medline25
EuroQol -- a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
CrossRef | Web of Science | Medline26
Ware JE ,Sherbourne CD . The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
CrossRef | Web of Science | Medline27
Mantel N ,Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748
Web of Science | Medline28
Simonneau G ,Barst RJ ,Galie N , et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804
Web of Science | Medline29
Rubin LJ ,Badesch DB ,Barst RJ , et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903[Erratum, N Engl J Med 2002;346:1258.]
Full Text | Web of Science | Medline30
Badesch DB ,Tapson VF ,McGoon MD , et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000;132:425-434
Web of Science | Medline31
Galie N ,Humbert M ,Vachiery JL , et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502
CrossRef | Web of Science | Medline32
McLaughlin VV ,Genthner DE ,Panella MM ,Rich S . Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277
Full Text | Web of Science | Medline33
Olschewski H ,Rohde B ,Behr J , et al. Comparison of inhalation of the prostacyclin analogue iloprost using different nebulizer systems in patients suffering from pulmonary hypertension. Chest 2000;118:Suppl:136S-136S abstract.
- Citing Articles (366)
Citing Articles
1
Cécile Tissot, Maurice Beghetti. 2012. Pediatric Pulmonary Hypertension. , 730-752.
CrossRef2
Suzanne M. D’Addio, John Gar Yan Chan, Philip Chi Lip Kwok, Robert K. Prud’homme, Hak-Kim Chan. (2012) Constant size, variable density aerosol particles by ultrasonic spray freeze drying. International Journal of Pharmaceutics
CrossRef3
Roberto Badagliacca, Beatrice Pezzuto, Roberto Poscia, Massimo Mancone, Silvia Papa, Serena Marcon, Gabriele Valli, Gennaro Sardella, Fabio Ferrante, Carlo Iacoboni, Daniela Parola, Francesco Fedele, Carmine Dario Vizza. (2012) Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation
CrossRef4
Mai Hazekawa, Yoshiki Sakai, Miyako Yoshida, Tamami Haraguchi, Takahiro Uchida. (2012) Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion. Journal of Pharmacy and Pharmacologyno-no
CrossRef5
Roderick W.C. Scherptong, Ivo R. Henkens, Gijs F.L. Kapel, Cees A. Swenne, Klaas W. van Kralingen, Menno V. Huisman, Annemie J.M. Schuerwegh, Jeroen J. Bax, Ernst E. vd Wall, Martin J. Schalij, Hubert W. Vliegen. (2012) Diagnosis and mortality prediction in pulmonary hypertension: The value of the electrocardiogram-derived ventricular gradient. Journal of Electrocardiology
CrossRef6
D. Payen. (2011) Le monoxyde d’azote : quelle place en réanimation ?. Réanimation
CrossRef7
Vallerie V. McLaughlin, Melinda Davis, William Cornwell. (2011) Pulmonary Arterial Hypertension. Current Problems in Cardiology 36:12, 461-517
CrossRef8
Mae M. Centeno. (2011) Pulmonary Arterial Hypertension. Critical Care Nursing Clinics of North America 23:4, 645-659
CrossRef9
H. Ardeschir Ghofrani, Oliver Distler, Felix Gerhardt, Matthias Gorenflo, Ekkehard Grünig, Walter E. Haefeli, Matthias Held, Marius M. Hoeper, Christian M. Kähler, Harald Kaemmerer, Hans Klose, Volker Köllner, Bruno Kopp, Siegrun Mebus, Andreas Meyer, Oliver Miera, David Pittrow, Gabriela Riemekasten, Stephan Rosenkranz, Dietmar Schranz, Robert Voswinckel, Horst Olschewski. (2011) Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology 154, S20-S33
CrossRef10
Moritz Beck-Broichsitter, Olivia M. Merkel, Thomas Kissel. (2011) Controlled pulmonary drug and gene delivery using polymeric nano-carriers. Journal of Controlled Release
CrossRef11
E. S. Hoendermis. (2011) Pulmonary arterial hypertension: an update. Netherlands Heart Journal
CrossRef12
Henrik ten Freyhaus, Daniel Dumitrescu, Eva Berghausen, Marius Vantler, Evren Caglayan, Stephan Rosenkranz. (2011) Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opinion on Investigational Drugs1-16
CrossRef13
James M. Hunt, Todd M. Bull. (2011) Clinical Review of Pulmonary Embolism: Diagnosis, Prognosis, and Treatment. Medical Clinics of North America 95:6, 1203-1222
CrossRef14
Matthew Ferrantino, R James White. (2011) Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 12:16, 2583-2593
CrossRef15
L. Arnaud, C. Agard, J. Haroche, P. Cacoub, J.-C. Piette, Z. Amoura. (2011) Hypertension artérielle pulmonaire associée au lupus systémique. La Revue de Médecine Interne 32:11, 689-697
CrossRef16
Amadea M. Martischnig, Alexander Tichy, Mariam Nikfardjam, Gottfried Heinz, Irene M. Lang, Diana Bonderman. (2011) Inhaled Iloprost for Patients With Precapillary Pulmonary Hypertension and Right-Side Heart Failure. Journal of Cardiac Failure 17:10, 813-818
CrossRef17
Maria Klara Frey, Irene Lang. (2011) Pulmonale Hypertension. Wiener klinische Wochenschrift Education 6:3, 78-93
CrossRef18
Moritz Beck-Broichsitter, Pia Kleimann, Tobias Gessler, Werner Seeger, Thomas Kissel, Thomas Schmehl. (2011) Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: Formulation aspects and nanoparticle stability to nebulization. International Journal of Pharmaceutics
CrossRef19
Moritz Beck-Broichsitter, Thomas Schmehl, Tobias Gessler, Werner Seeger, Thomas Kissel. (2011) Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. Journal of Controlled Release
CrossRef20
Luigi A. Gabrielli, Pablo F. Castro, Ivan Godoy, Rosemarie Mellado, Robert C. Bourge, Hernan Alcaino, Mario Chiong, Douglas Greig, Hugo E. Verdejo, Mario Navarro, Rafael Lopez, Barbra Toro, Clara Quiroga, Guillermo Díaz-Araya, Sergio Lavandero, Lorena Garcia. (2011) Systemic Oxidative Stress and Endothelial Dysfunction is Associated With an Attenuated Acute Vascular Response to Inhaled Prostanoid in Pulmonary Artery Hypertension Patients. Journal of Cardiac Failure
CrossRef21
Jérôme Le Pavec, Reda E. Girgis, Noah Lechtzin, Stephen C. Mathai, David Launay, Laura K. Hummers, Ari Zaiman, Olivier Sitbon, Gérald Simonneau, Marc Humbert, Paul M. Hassoun. (2011) Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis & Rheumatism 63:8, 2456-2464
CrossRef22
Richa Agarwal, Mardi Gomberg-Maitland. (2011) Current therapeutics and practical management strategies for pulmonary arterial hypertension. American Heart Journal 162:2, 201-213
CrossRef23
Johann Strumpher, Eric Jacobsohn. (2011) Pulmonary Hypertension and Right Ventricular Dysfunction: Physiology and Perioperative Management. Journal of Cardiothoracic and Vascular Anesthesia 25:4, 687-704
CrossRef24
Kengo F. Kusano. (2011) Treatment for pulmonary hypertension including lung transplantation. General Thoracic and Cardiovascular Surgery 59:8, 538-546
CrossRef25
Dermot S. O'Callaghan, Laurent Savale, David Montani, Xavier Jaïs, Olivier Sitbon, Gérald Simonneau, Marc Humbert. (2011) Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology 8:9, 526-538
CrossRef26
Yan-Yan Xu, Cui-Tao Lu, Hong-Xing Fu, Ying-Zheng Zhao, Wei Yang, Xing Li, Lu Zhang, Xiao-Kun Li, Ming Zhang. (2011) Comparing the Enhancement Efficiency Between Liposomes and Microbubbles for Insulin Pulmonary Absorption. Diabetes Technology & Therapeutics 13:7, 759-765
CrossRef27
Vivek Gupta, Fakhrul Ahsan. (2011) Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator. International Journal of Pharmaceutics 413:1-2, 51-62
CrossRef28
Robyn J. Barst, Ronald J. Oudiz, Anthony Beardsworth, Bruce H. Brundage, Gerald Simonneau, Hossein A. Ghofrani, David P. Sundin, Nazzareno Galiè. (2011) Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation 30:6, 632-643
CrossRef29
Zeenat Safdar. (2011) Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respiratory Medicine 105:6, 818-827
CrossRef30
André P. Lourenço, Dulce Fontoura, Tiago Henriques-Coelho, Adelino F. Leite-Moreira. (2011) Current pathophysiological concepts and management of pulmonary hypertension. International Journal of Cardiology
CrossRef31
Geoff Strange, Anne Keogh, Brad Dalton, Eli Gabbay. (2011) Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, 253-263
CrossRef32
Paul A. Corris. (2011) Alternatives to Lung Transplantation: Treatment of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 32:2, 399-410
CrossRef33
Ke-He Ruan, Anita Mohite, Shui-Ping So, Cheng-Huai Ruan. (2011) Establishing novel prostacyclin-synthesizing cells with therapeutic potential against heart diseases. International Journal of Cardiology
CrossRef34
(2011) Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine 364:17, 1677-1678
Full Text35
Ralf Ewert, Sven Gläser, Tom Bollmann, Christoph Schäper. (2011) Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Review of Respiratory Medicine 5:2, 145-152
CrossRef36
Richard A. Krasuski, Ganesh P. Devendra, Stephen A. Hart, Andrew Wang, J. Kevin Harrison, Thomas M. Bashore. (2011) Response to Inhaled Nitric Oxide Predicts Survival in Patients With Pulmonary Hypertension. Journal of Cardiac Failure 17:4, 265-271
CrossRef37
Hanish Bagga, Karen S.W. Chia, Diane Freeman, Lyn Hales, David S. Henderson, Eugene Kotlyar, David Law, Pradeen Mudholkar, Cheryl Tulk, Jon H. Waites, Peter K.K. Wong. (2011) The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia. Australian Journal of Rural Health 19:2, 89-94
CrossRef38
Bhashkar Mukherjee, Luke Howard. (2011) Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. Expert Review of Respiratory Medicine 5:2, 191-205
CrossRef39
Jean-Luc Vachiéry. (2011) Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. Advances in Therapy 28:4, 251-269
CrossRef40
C. Mélot, R. Naeije. 2011. Pulmonary Vascular Diseases. .
CrossRef41
Ralph T Schermuly, Wiebke Janssen, Norbert Weissmann, Johannes-Peter Stasch, Friedrich Grimminger, Hossein Ardeschir Ghofrani. (2011) Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs567-576
CrossRef42
A. Keogh, G. Strange, E. Kotlyar, T. Williams, D. Kilpatrick, P. Macdonald, K. Brown, A. Pidoux, F. Kermeen, P. Steele, B. Dalton, E. Gabbay. (2011) Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Internal Medicine Journal 41:3, 235-244
CrossRef43
David M. Smadja, Laetitia Mauge, Pascale Gaussem, Clément d’Audigier, Dominique Israel-Biet, David S. Celermajer, Damien Bonnet, Marilyne Lévy. (2011) Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis 14:1, 17-27
CrossRef44
Julie John, Harold Palevsky. (2011) Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Review of Clinical Pharmacology 4:2, 197-205
CrossRef45
Frank Reichenberger, Ann Mainwood, Nicholas W. Morrell, Jayan Parameshwar, Joanna Pepke-Zaba. (2011) Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 24:1, 169-173
CrossRef46
Jeanne Houtchens, Douglas Martin, James R. Klinger. (2011) Diagnosis and Management of Pulmonary Arterial Hypertension. Pulmonary Medicine 2011, 1-13
CrossRef47
Moritz Beck-Broichsitter, Thomas Schmehl, Werner Seeger, Tobias Gessler. (2011) Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models. Journal of Nanomaterials 2011, 1
CrossRef48
Soumya Chatterjee. (2011) Pulmonary Hypertension in Systemic Sclerosis. Seminars in Arthritis and Rheumatism 41:1, 19
CrossRef49
Changhwan Kim, Yong Bum Park. (2011) Pharmacotherapy for pulmonary arterial hypertension. Journal of the Korean Medical Association 54:12, 1299
CrossRef50
Kazuya Hosokawa, Hatsue Ishibashi-Ueda, Takuya Kishi, Norifumi Nakanishi, Shingo Kyotani, Hitoshi Ogino. (2011) Histopathological Multiple Recanalized Lesion Is Critical Element of Outcome After Pulmonary Thromboendarterectomy. International Heart Journal 52:6, 377-381
CrossRef51
Satyan Lakshminrusimha, Vasanth H. Kumar. 2011. Diseases of Pulmonary Circulation. , 632-656.
CrossRef52
William R. Auger, Nick H. Kim, Terence K. Trow. (2010) Chronic Thromboembolic Pulmonary Hypertension. Clinics in Chest Medicine 31:4, 741-758
CrossRef53
Sherif Afifi, Shahriar Shayan, Abbas Al-Qamari. (2010) Pulmonary Hypertension and Right Ventricular Function. International Anesthesiology Clinics 47:1, 97-120
CrossRef54
Friedrich Grimminger, Ralph T. Schermuly, Hossein A. Ghofrani. (2010) Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery 9:12, 956-970
CrossRef55
M.T.R. Roofthooft, R.L.E. van Loon, R.M.F. Berger. (2010) Management of Pulmonary Arterial Hypertension in Children. Paediatric Respiratory Reviews 11:4, 240-245
CrossRef56
Zeenat Safdar. (2010) Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension. Clinical Drug Investigation 30:12, 811-826
CrossRef57
Michael A. Mathier, Susanne McDevitt, Rajan Saggar. (2010) Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. The Journal of Heart and Lung Transplantation 29:11, 1210-1217
CrossRef58
Meredith E Pugh, Anna R Hemnes. (2010) Pulmonary hypertension in women. Expert Review of Cardiovascular Therapy 8:11, 1549-1558
CrossRef59
Hans-Juergen Seyfarth, Michael Halank, Heinrike Wilkens, Hans-Joachim Schäfers, Ralf Ewert, Martin Riedel, Ernst Schuster, Hans Pankau, Stefan Hammerschmidt, Hubert Wirtz. (2010) Standard PAH therapy improves long term survival in CTEPH patients. Clinical Research in Cardiology 99:9, 553-556
CrossRef60
N. Galie, M. Palazzini, A. Manes. (2010) Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. European Heart Journal 31:17, 2080-2086
CrossRef61
Sevdalina Lambova, Ulf Müller-Ladner. (2010) Pulmonary arterial hypertension in systemic sclerosis. Autoimmunity Reviews 9:11, 761-770
CrossRef62
Dermot S. O’Callaghan, Laurent Savale, Xavier Jaïs, Delphine Natali, David Montani, Marc Humbert, Gérald Simonneau, Olivier Sitbon. (2010) Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine 104, S74-S80
CrossRef63
Adam Torbicki. (2010) Enfermedad tromboembólica pulmonar. Manejo clínico de la enfermedad aguda y crónica. Revista Española de Cardiología 63:7, 832-849
CrossRef64
Deborah H. McCollister, Michelle Beutz, Vallerie McLaughlin, John Rumsfeld, Frederick A. Masoudi, Mark Tripputi, Thomas Yaeger, Philippe Weintraub, David B. Badesch. (2010) Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status. Psychosomatics 51:4, 339-339.e8
CrossRef65
Dimitar Sajkov, Nikolai Petrovsky, Paolo Palange. (2010) Management of dyspnea in advanced pulmonary arterial hypertension. Current Opinion in Supportive and Palliative Care 4:2, 76-84
CrossRef66
John Granton. (2010) Outcomes in pulmonary hypertension: Beyond 40 metres. Canadian Journal of Cardiology 26, 12B-16B
CrossRef67
Mark R. Toshner, Deepa Gopalan, Jay Suntharalingam, Carmen Treacy, Elaine Soon, Karen K. Sheares, Nicholas W. Morrell, Nicholas Screaton, Joanna Pepke-Zaba. (2010) Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation 29:6, 610-615
CrossRef68
M.M. Hoeper, H.A. Ghofrani, M. Gorenflo, E. Grünig, S. Rosenkranz, D. Schranz. (2010) Diagnostik und Therapie der pulmonalen Hypertonie. Der Kardiologe 4:3, 189-207
CrossRef69
Richard N. Channick. (2010) Pulmonary hypertension: Classification and treatment. Canadian Journal of Cardiology 26, 5B-11B
CrossRef70
Nazzareno Galiè, Massimiliano Palazzini, Enri Leci, Alessandra Manes. (2010) Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. Revista Española de Cardiología 63:6, 708-724
CrossRef71
H.-A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Gall, W. Seeger, F. Grimminger. (2010) Aktuelle Therapie der pulmonal-arteriellen Hypertonie. Der Pneumologe 7:3, 192-199
CrossRef72
Nazzareno Galiè, Gérald Simonneau, Robyn J Barst, David Badesch, Lewis Rubin. (2010) Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Current Opinion in Pulmonary Medicine 16:Suppl 1, S11-S19
CrossRef73
Joe R. Anderson, James J. Nawarskas. (2010) Pharmacotherapeutic Management of Pulmonary Arterial Hypertension. Cardiology in Review 18:3, 148-162
CrossRef74
K. Iversen, A. S. Jensen, T. V. Jensen, N. G. Vejlstrup, L. Sondergaard. (2010) Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. European Heart Journal 31:9, 1124-1131
CrossRef75
J Gerry Coghlan, Janet Pope, Christopher P Denton. (2010) Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. Current Opinion in Pulmonary Medicine 16:Suppl 1, S27-S34
CrossRef76
Vallerie V. McLaughlin, Raymond L. Benza, Lewis J. Rubin, Richard N. Channick, Robert Voswinckel, Victor F. Tapson, Ivan M. Robbins, Horst Olschewski, Melvyn Rubenfire, Werner Seeger. (2010) Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 55:18, 1915-1922
CrossRef77
Manuel Ramos-Casals, Vicent Fonollosa-Pla, Pilar Brito-Zerón, Antoni Sisó-Almirall. (2010) Targeted therapy for systemic sclerosis: how close are we?. Nature Reviews Rheumatology 6:5, 269-278
CrossRef78
Adriano R. Tonelli, Hassan Alnuaimat, Kamal Mubarak. (2010) Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respiratory Medicine 104:4, 481-496
CrossRef79
Teena Abraham, Gary Wu, Fabienne Vastey, Jonathan Rapp, Nasser Saad, Eric Balmir. (2010) Role of Combination Therapy in the Treatment of Pulmonary Arterial Hypertension. Pharmacotherapy 30:4, 390-404
CrossRef80
Rudolf E. Stauber, Horst Olschewski. (2010) Portopulmonary hypertension: short review. European Journal of Gastroenterology & Hepatology 22:4, 385-390
CrossRef81
DG Kiely, R Condliffe, V Webster, GH Mills, I Wrench, SV Gandhi, K Selby, IJ Armstrong, L Martin, ES Howarth, FA Bu’Lock, P Stewart, CA Elliot. (2010) Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG: An International Journal of Obstetrics & Gynaecology 117:5, 565-574
CrossRef82
Anna A. Birukova, Dylan Burdette, Nurgul Moldobaeva, Junjie Xing, Panfeng Fu, Konstantin G. Birukov. (2010) Rac GTPase is a hub for protein kinase A and Epac signaling in endothelial barrier protection by cAMP. Microvascular Research 79:2, 128-138
CrossRef83
D. Launay, O. Sitbon, J. Le Pavec, L. Savale, C. Tcherakian, A. Yaici, L. Achouh, F. Parent, X. Jais, G. Simonneau, M. Humbert. (2010) Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 49:3, 490-500
CrossRef84
D. Dunbar Ivy. (2010) Prostacyclin in the intensive care setting. Pediatric Critical Care Medicine 11, S41-S45
CrossRef85
Khaled Abdelhady, Patricia Gramling-Babb, Sawsan Awad, Abdallah G Rebeiz, Payam Salehi, Ahmad Chaudhry, Michael Diodato, Lona Ernst Rizkallah, Edgar G Chedrawy, Sunil Prasad, Malek G Massad. (2010) Current and future therapy for pulmonary hypertension in patients with right and left heart failure. Expert Review of Cardiovascular Therapy 8:2, 241-250
CrossRef86
Jagdish Hiremath, Sadagopa Thanikachalam, Keyur Parikh, Somasundaram Shanmugasundaram, Sudhakar Bangera, Leland Shapiro, Gregory B. Pott, Cindy L. Vnencak-Jones, Carl Arneson, Michael Wade, R. James White. (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. The Journal of Heart and Lung Transplantation 29:2, 137-149
CrossRef87
G.-P. Diller, H. Baumgartner. (2010) Pulmonary arterial hypertension in adults with congenital heart disease. International Journal of Clinical Practice 64, 13-24
CrossRef88
Alejandro Macchia, Roberto Marchioli, Gianni Tognoni, Marco Scarano, RosaMaria Marfisi, Luigi Tavazzi, Stuart Rich. (2010) Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal 159:2, 245
CrossRef89
Bing He, Fengwen Zhang, Xueying Li, Chaoshu Tang, Guosheng Lin, Junbao Du, Hongfang Jin. (2010) Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension. Circulation Journal 74:7, 1458-1464
CrossRef90
Peter K. Wung, Fredrick M. Wigley. 2010. Management of Systemic Sclerosis and Raynaud's Phenomenon. , 157-165.
CrossRef91
Zhi-Cheng Jing, Geoff Strange, Xian-Yang Zhu, Da-Xin Zhou, Jie-Yan Shen, Hong Gu, Zhen-Kun Yang, Xin Pan, Mei-Xiang Xiang, Hua Yao, Dong-Bao Zhao, Brad S. Dalton, Zhuo-Li Zhang, Yong Wang, Xian-Sheng Cheng, Yue-Jin Yang. (2010) Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation 29:2, 150
CrossRef92
Kamal K. Mubarak. (2010) A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respiratory Medicine 104:1, 9-21
CrossRef93
Horst Olschewski, Marius M. Hoeper, Juergen Behr, Ralf Ewert, Andreas Meyer, Mathias M. Borst, Jörg Winkler, Michael Pfeifer, Heinrike Wilkens, Hossein Ardeschir Ghofrani, Sylvia Nikkho, Werner Seeger. (2010) Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine 104:5, 731
CrossRef94
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery, Joan Albert Barberá, Maurice Beghetti, Paul Corris, Sean Gaine, J. Simon Gibbs, Miguel Ángel Gómez-Sánchez, Guillaume Jondeau, Walter Klepetko, Christian Opitz, Andrew Peacock, Lewis Rubin, Michael Zellweger, Gerald Simonneau. (2009) Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Revista Española de Cardiología 62:12, 1464.e1-1464.e58
CrossRef95
Farouk Mookadam, Martina Mookadam, Panupong Jiamsripong, Ramil Goel. (2009) Pulmonary thromboembolic disease spectrum: diagnostic and therapeutic strategies. Expert Review of Cardiovascular Therapy 7:11, 1421-1428
CrossRef96
, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, K. McGregor, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. Vardas, P. Widimsky, , U. Sechtem, N. Al Attar, F. Andreotti, M. Aschermann, R. Asteggiano, R. Benza, R. Berger, D. Bonnet, M. Delcroix, L. Howard, A. N. Kitsiou, I. Lang, A. Maggioni, J. E. Nielsen-Kudsk, M. Park, P. Perrone-Filardi, S. Price, M. T. S. Domenech, A. Vonk-Noordegraaf, J. L. Zamorano. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal 30:20, 2493-2537
CrossRef97
Margaret C. Garin, Leslie Clark, Elinor C.G. Chumney, Kit N. Simpson, Kristin B. Highland. (2009) Cost-Utility of Treatments for Pulmonary Arterial Hypertension. Clinical Drug Investigation 29:10, 635-646
CrossRef98
M. Claussen, G. Riemekasten, M.M. Hoeper. (2009) Pulmonal arterielle Hypertonie bei Kollagenosen. Zeitschrift für Rheumatologie 68:8, 630-638
CrossRef99
R. Voswinckel, F. Reichenberger, H. Gall, W. Seeger, F. Grimminger, H.A. Ghofrani. (2009) Therapie der pulmonalarteriellen Hypertonie. Der Internist 50:9, 1101-1110
CrossRef100
Geoff STRANGE, Peter NASH. (2009) The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. International Journal of Rheumatic Diseases 12:3, 192-206
CrossRef101
Manuel López-Meseguer, Antonio Román, Víctor Monforte, Carlos Bravo, Joan Solé, Ferran Morell. (2009) Trasplante bipulmonar en hipertensión pulmonar. Una serie de 15 pacientes. Archivos de Bronconeumología 45:8, 366-370
CrossRef102
T. Rasekaba, A. L. Lee, M. T. Naughton, T. J. Williams, A. E. Holland. (2009) The six-minute walk test: a useful metric for the cardiopulmonary patient. Internal Medicine Journal 39:8, 495-501
CrossRef103
Javier F. Aduen, Ramon Castello, Marcelo M. Lozano, George N. Hepler, Cesar A. Keller, Francisco Alvarez, Robert E. Safford, Julia E. Crook, Michael G. Heckman, Charles D. Burger. (2009) An Alternative Echocardiographic Method to Estimate Mean Pulmonary Artery Pressure: Diagnostic and Clinical Implications. Journal of the American Society of Echocardiography 22:7, 814-819
CrossRef104
Fredrick M. Wigley. (2009) Vascular Disease in Scleroderma. Clinical Reviews in Allergy & Immunology 36:2-3, 150-175
CrossRef105
Maria J. Ruiz-Cano, Pilar Escribano, Rafael Alonso, Juan Delgado, Patricia Carreira, Teresa Velazquez, Miguel A. Gomez Sanchez, Carlos Sáenz de la Calzada. (2009) Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Disease–related Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 28:6, 621-627
CrossRef106
Cecile Tissot, Maurice Beghetti. (2009) Advances in therapies for pediatric pulmonary arterial hypertension. Expert Review of Respiratory Medicine 3:3, 265-282
CrossRef107
David B. Badesch, Hunter C. Champion, Miguel Angel Gomez Sanchez, Marius M. Hoeper, James E. Loyd, Alessandra Manes, Michael McGoon, Robert Naeije, Horst Olschewski, Ronald J. Oudiz, Adam Torbicki. (2009) Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S55-S66
CrossRef108
V. McLaughlin, M. Humbert, G. Coghlan, P. Nash, V. Steen. (2009) Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology 48:Supplement 3, iii25-iii31
CrossRef109
Robyn J. Barst, Duncan Stewart. (2009) Conventional and targeted medical therapies. Cardiology in the Young 19:S1, 28
CrossRef110
Scott Gleim, Zsolt Kasza, Kathleen Martin, John Hwa. (2009) Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Current Atherosclerosis Reports 11:3, 227-235
CrossRef111
Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Robyn J. Barst, Harrison W. Farber, Jonathan R. Lindner, Michael A. Mathier, Michael D. McGoon, Myung H. Park, Robert S. Rosenson, Lewis J. Rubin, Victor F. Tapson, John Varga. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology 53:17, 1573-1619
CrossRef112
Peter M. Mourani, Marci K. Sontag, D. Dunbar Ivy, Steven H. Abman. (2009) Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung Disease. The Journal of Pediatrics 154:3, 379-384.e2
CrossRef113
Aydin Uzunpinar, Mehmet Cilingiroglu. (2009) Pulmonary arterial hypertension. Current Atherosclerosis Reports 11:2, 139-145
CrossRef114
Karen M. Olsson, Marius M. Hoeper. (2009) Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discovery Today 14:5-6, 284-290
CrossRef115
Robert Voswinckel, Frank Reichenberger, Henning Gall, Thomas Schmehl, Tobias Gessler, Ralph Theo Schermuly, Friedrich Grimminger, Lewis J. Rubin, Werner Seeger, Hossein A. Ghofrani, Horst Olschewski. (2009) Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 22:1, 50-56
CrossRef116
Moritz Beck-Broichsitter, Julia Gauss, Claudia B. Packhaeuser, Kerstin Lahnstein, Thomas Schmehl, Werner Seeger, Thomas Kissel, Tobias Gessler. (2009) Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. International Journal of Pharmaceutics 367:1-2, 169-178
CrossRef117
M. D. McGoon, G. C. Kane. (2009) Pulmonary Hypertension: Diagnosis and Management. Mayo Clinic Proceedings 84:2, 191-207
CrossRef118
Erika B. Rosenzweig, Robyn J. Barst. (2009) Pulmonary arterial hypertension in children: A Medical Update. The Indian Journal of Pediatrics 76:1, 77-81
CrossRef119
Christopher J. Rhodes, Alexandra Davidson, J. Simon R. Gibbs, John Wharton, Martin R. Wilkins. (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacology & Therapeutics 121:1, 69-88
CrossRef120
Vallerie V. McLaughlin, David B. Badesch, Marion Delcroix, Thomas R. Fleming, Sean P. Gaine, Nazzareno Galiè, J. Simon R. Gibbs, Nick H. Kim, Ronald J. Oudiz, Andrew Peacock, Steeve Provencher, Olivier Sitbon, Victor F. Tapson, Werner Seeger. (2009) End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S97
CrossRef121
Antonio Román Broto, Víctor Monforte Torres. (2009) Tratamiento combinado de la hipertensión arterial pulmonar. Archivos de Bronconeumología 45:1, 36-40
CrossRef122
Robyn J. Barst, J. Simon R. Gibbs, Hossein A. Ghofrani, Marius M. Hoeper, Vallerie V. McLaughlin, Lewis J. Rubin, Olivier Sitbon, Victor F. Tapson, Nazzareno Galiè. (2009) Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S78
CrossRef123
Takeyoshi Kunieda, Norifumi Nakanishi, Hiromi Matsubara, Tohru Ohe, Yoshiaki Okano, Hirobumi Kondo, Masaharu Nishimura, Kunio Shirato, Nobuhiro Tanabe, Satoshi Homma, Shunji Yoshida, Shigeko Inokuma, Makoto Kodama, Takao Koike, Hitoshi Hishida. (2009) Effects of Long-Acting Beraprost Sodium (TRK-100STP) in Japanese Patients With Pulmonary Arterial Hypertension. International Heart Journal 50:4, 513-529
CrossRef124
Zeenat Safdar. (2009) Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan. Respiratory Medicine 103:11, 1688
CrossRef125
(2009) Terapias respiratorias. Archivos de Bronconeumología 45, 2-28
CrossRef126
Thierry Sottiaux, Caroline Dresse. 2009. Aérosolthérapie chez le patient en ventilation mécanique. , 325-334.
CrossRef127
Francisco José García Hernández, María Jesús Castillo Palma, Rocío González León, Rocío Garrido Rasco, Celia Ocaña Medina, Julio Sánchez Román. (2008) Experiencia en el tratamiento de la hipertensión arterial pulmonar con imatinib. Archivos de Bronconeumología 44:12, 689-691
CrossRef128
Ralf Ewert, Sven Gläser, Christian Opitz. (2008) Iloprost in pulmonary hypertension. Expert Review of Respiratory Medicine 2:6, 689-702
CrossRef129
J. Sánchez Román, F.J. García Hernández, M.J. Castillo Palma, R. González León. (2008) Tratamiento de la hipertensión arterial pulmonar. Estrategias terapéuticas. Fármacos. Criterios de empleo. Indicaciones. Contraindicaciones. Posología. Efectos secundarios. Criterios de asociación y sustitución. Medicine - Programa de Formación Médica Continuada Acreditado 10:23, 1566-1574
CrossRef130
Xavier Jaïs, Andrea M. D'Armini, Pavel Jansa, Adam Torbicki, Marion Delcroix, Hossein A. Ghofrani, Marius M. Hoeper, Irene M. Lang, Eckhard Mayer, Joanna Pepke-Zaba, Loïc Perchenet, Adele Morganti, Gérald Simonneau, Lewis J. Rubin. (2008) Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology 52:25, 2127-2134
CrossRef131
Justin S. W. Taylor, Julian P. J. Halcox. (2008) PDE5 inhibitors and pulmonary hypertension. Current Sexual Health Reports 5:4, 171-178
CrossRef132
Carole A. Warnes, Roberta G. Williams, Thomas M. Bashore, John S. Child, Heidi M. Connolly, Joseph A. Dearani, Pedro del Nido, James W. Fasules, Thomas P. Graham, Ziyad M. Hijazi, Sharon A. Hunt, Mary Etta King, Michael J. Landzberg, Pamela D. Miner, Martha J. Radford, Edward P. Walsh, Gary D. Webb. (2008) ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. Journal of the American College of Cardiology 52:23, e143-e263
CrossRef133
Lennert Slobbe, Eric Boersma, Bart J.A. Rijnders. (2008) Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial. Pulmonary Pharmacology & Therapeutics 21:6, 855-859
CrossRef134
Carole A. Warnes, Roberta G. Williams, Thomas M. Bashore, John S. Child, Heidi M. Connolly, Joseph A. Dearani, Pedro del Nido, James W. Fasules, Thomas P. Graham, Ziyad M. Hijazi, Sharon A. Hunt, Mary Etta King, Michael J. Landzberg, Pamela D. Miner, Martha J. Radford, Edward P. Walsh, Gary D. Webb. (2008) ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology 52:23, 1890-1947
CrossRef135
Keiichi Hirose, Akira Marui, Yoshio Arai, Toshihiro Kushibiki, Yu Kimura, Hisashi Sakaguchi, Huang Yuang, B.I.R. Shyamal Chandra, Tadashi Ikeda, Shigeru Amano, Yasuhiko Tabata, Masashi Komeda. (2008) Novel approach with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension. The Journal of Thoracic and Cardiovascular Surgery 136:5, 1250-1256
CrossRef136
Robert Voswinckel, Frank Reichenberger, Beate Enke, Andre Kreckel, Stefanie Krick, Henning Gall, Ralph Theo Schermuly, Friedrich Grimminger, Lewis J. Rubin, Horst Olschewski, Werner Seeger, Hossein A. Ghofrani. (2008) Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 21:5, 824-832
CrossRef137
N. Galie, A. Manes, L. Negro, M. Palazzini, M. L. Bacchi-Reggiani, A. Branzi. (2008) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. European Heart Journal 30:4, 394-403
CrossRef138
Madhavi T. Reddy, Hamang Patel, Hector O. Ventura. (2008) Successful Transition From Intravenous to Inhaled Prostacyclin in a Patient With Pulmonary Hypertension and Right Ventricular Failure. Congestive Heart Failure 14:5, 285-286
CrossRef139
Patricia Macedo, Omar S. Usmani. (2008) Inhaled Drug Therapy in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 15:5, 239-247
CrossRef140
Geoff STRANGE, Anne M. KEOGH, Trevor J. WILLIAMS, John WLODARCZYK, Keith D. MCNEIL, Eli GABBAY. (2008) Bosentan therapy in patients with pulmonary arterial hypertension: The relationship between improvements in 6 minute walk distance and quality of life. Respirology 13:5, 674-682
CrossRef141
Dermot S. O'Callaghan. (2008) Emerging treatments for pulmonary arterial hypertension. The Clinical Respiratory Journal 2:3, 132-140
CrossRef142
N Galiè, LJ Rubin, MM Hoeper, P Jansa, H Al-Hiti, GMB Meyer, E Chiossi, A Kusic-Pajic, G Simonneau. (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet 371:9630, 2093-2100
CrossRef143
Michael Winterhalter, Andre Simon, Stefan Fischer, Niels Rahe-Meyer, Nicoletta Chamtzidou, Hartmut Hecker, Janusz Zuk, Siegfried Piepenbrock, Martin Strüber. (2008) Comparison of Inhaled Iloprost and Nitric Oxide in Patients With Pulmonary Hypertension During Weaning From Cardiopulmonary Bypass in Cardiac Surgery: A Prospective Randomized Trial. Journal of Cardiothoracic and Vascular Anesthesia 22:3, 406-413
CrossRef144
Renata Villela, Sai Yan Yuen, Janet E. Pope, Murray Baron, . (2008) Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. Arthritis & Rheumatism 59:5, 706-713
CrossRef145
M. Lelgemann, R. Francke. (2008) Seltene Erkrankungen in professionellen Versorgungssystemen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 51:5, 509-518
CrossRef146
Raymond J. Foley. (2008) Right Ventricular Failure in the Critically Ill Patient With Pulmonary Arterial Hypertension. Clinical Pulmonary Medicine 15:3, 161-166
CrossRef147
Bart J. Rijnders, Jan J. Cornelissen, Lennert Slobbe, Martin J. Becker, Jeanette K. Doorduijn, Wim C. J. Hop, Elisabeth J. Ruijgrok, Bob Löwenberg, Arnold Vulto, Pieternella J. Lugtenburg, Siem de Marie. (2008) Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled Trial. Clinical Infectious Diseases 46:9, 1401-1408
CrossRef148
P. Cacoub, Z. Amoura, D. Langleben. (2008) La prise en charge thérapeutique de l’hypertension artérielle pulmonaire par les antagonistes des récepteurs de l’endothéline en 2008. La Revue de Médecine Interne 29:4, 283-289
CrossRef149
Tobias Gessler, Werner Seeger, Thomas Schmehl. (2008) Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21:1, 1-12
CrossRef150
J. Sánchez Román, F.J. García Hernández, M.J. Castillo Palma, C. Ocaña Medina. (2008) Diagnóstico y tratamiento de la hipertensión pulmonar. Revista Clínica Española 208:3, 142-155
CrossRef151
Lewis J. Rubin. (2008) Treatment of Pulmonary Arterial Hypertension Due to Scleroderma: Challenges for the Future. Rheumatic Disease Clinics of North America 34:1, 191-197
CrossRef152
Myung H. Park. (2008) Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheterization and Cardiovascular Interventions 71:2, 205-213
CrossRef153
Ralf Geiger, Axel Kleinsasser, Stephan Meier, Nikolaus Neu, Werner Pajk, Victoria Fischer, Benedict Treml, Joerg I. Stein, Alexander Loeckinger. (2008) Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration. Intensive Care Medicine 34:2, 368-376
CrossRef154
Tobias Gessler, Werner Seeger, Thomas Schmehl. (2008) Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine 0:0, 080116123756336-12
CrossRef155
Steven H. Abman. 2008. Cor Pulmonale and Pulmonary Complications of Cardiac Disease. , 735-757.
CrossRef156
S. REX, G. SCHAELTE, S. METZELDER, S. FLIER, E. E. C. DE WAAL, R. AUTSCHBACH, R. ROSSAINT, W. BUHRE. (2008) Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiologica Scandinavica 52:1, 65-72
CrossRef157
Oliver Distler, Frank Behrens, David Pittrow, Doerte Huscher, Christopher P. Denton, Ivan Foeldvari, Marc Humbert, Marco Matucci-Cerinic, Peter Nash, Christian F. Opitz, Lewis J. Rubin, James R. Seibold, Daniel E. Furst. (2008) Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. Arthritis & Rheumatism 59:6, 867
CrossRef158
Eli Gabbay, Robert G. Weintraub, Lewis J. Rubin. 2008. Pulmonary Arterial Hypertension. , 759-771.
CrossRef159
James A Driscoll, Murali M Chakinala. (2008) Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 9:1, 65-81
CrossRef160
Mardi Gomberg-Maitland, Thenappan Thenappan, Kamran Rizvi, Sonal Chandra, David M. Meads, Stephen P. McKenna. (2008) United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). The Journal of Heart and Lung Transplantation 27:1, 124
CrossRef161
D. Dunbar Ivy, Aimee K. Doran, Kelly J. Smith, George B. Mallory, Maurice Beghetti, Robyn J. Barst, Daniela Brady, Yuk Law, Donna Parker, Lori Claussen, Steven H. Abman. (2008) Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 51:2, 161-169
CrossRef162
Sabine Krug, Stefan Hammerschmidt, Hans Pankau, Hubert Wirtz, Hans-Jürgen Seyfarth. (2008) Acute Improved Hemodynamics following Inhaled Iloprost in Chronic Thromboembolic Pulmonary Hypertension. Respiration 76:2, 154-159
CrossRef163
H. Olschewski. (2008) Lungenembolie. Der Pneumologe 5:1, 45-54
CrossRef164
Erika B Rosenzweig, Robyn J Barst. (2008) Pulmonary arterial hypertension in children: a medical update. Current Opinion in Pediatrics 20:3, 288
CrossRef165
Richard N. Channick, Lewis J. Rubin. 2008. Pulmonary Vasodilators in COPD. , 699-704.
CrossRef166
Sabine Krug, Hans-Juergen Seyfarth, Andreas Hagendorff, Hubert Wirtz. (2007) Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. European Journal of Gastroenterology & Hepatology 19:12, 1140-1143
CrossRef167
M. Humbert. (2007) Traitement de l’hypertension artérielle pulmonaire idiopathique et associée à la sclérodermie systémique. La Revue de Médecine Interne 28, S273-S276
CrossRef168
J. M. Wryobeck, G. Lippo, V. McLaughlin, M. Riba, M. Rubenfire. (2007) Psychosocial Aspects of Pulmonary Hypertension: A Review. Psychosomatics 48:6, 467-475
CrossRef169
Todd M Bull. (2007) Screening and therapy of pulmonary hypertension in systemic sclerosis. Current Opinion in Rheumatology 19:6, 598-603
CrossRef170
Sheridan Henness, Fredrick M Wigley. (2007) Current drug therapy for scleroderma and secondary Raynaud??s phenomenon: evidence-based review. Current Opinion in Rheumatology 19:6, 611-618
CrossRef171
Christoph Hucklenbruch, Frank Hinder, Christian Berger, Christian Ertmer, Matthias Lange, Martin Westphal, Hugo Van Aken, Björn Ellger, Henning Dirk Stubbe. (2007) EFFECTS OF INHALED AEROSOLIZED ILOPROST AND INHALED NO ON PULMONARY CIRCULATION AND EDEMA FORMATION IN OVINE LUNG INJURY. Shock1
CrossRef172
Robert Naeije, Sandrine Huez. (2007) Expert opinion on available options treating pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 8:14, 2247-2265
CrossRef173
Neal Benedict, Amy Seybert, Michael A. Mathier. (2007) Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension. Clinical Therapeutics 29:10, 2134-2153
CrossRef174
Melvyn Rubenfire, Melike Bayram, Zachary Hector-Word. (2007) Pulmonary Hypertension in the Critical Care Setting: Classification, Pathophysiology, Diagnosis, and Management. Critical Care Clinics 23:4, 801-834
CrossRef175
Amadea Martischnig, Diana Bonderman. (2007) Pulmonale Hypertension. Wiener klinische Wochenschrift Education 2:2, 107-121
CrossRef176
Michael Dandel, Hans B. Lehmkuhl, Sead Mulahasanovic, Yuguo Weng, Dagmar Kemper, Onnen Grauhan, Christoph Knosalla, Roland Hetzer. (2007) Survival of Patients With Idiopathic Pulmonary Arterial Hypertension After Listing for Transplantation: Impact of Iloprost and Bosentan Treatment. The Journal of Heart and Lung Transplantation 26:9, 898-906
CrossRef177
S. Gaine, M. Gomberg-Maitland. (2007) What's new in pulmonary hypertension?. International Journal of Clinical Practice 61, 3-4
CrossRef178
Tomas Bratel, Lars Lagerstrand, Lars-Åke Brodin, Jacek Nowak, Ivar Randmaa. (2007) Ventilation–perfusion relationships in pulmonary arterial hypertension: Effect of intravenous and inhaled prostacyclin treatment. Respiratory Physiology & Neurobiology 158:1, 59-69
CrossRef179
Stephan Rosenkranz. (2007) Pulmonary hypertension: current diagnosis and treatment. Clinical Research in Cardiology 96:8, 527-541
CrossRef180
M Fontana, H Olschewski, A Olschewski, K-D Schlüter. (2007) Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. British Journal of Pharmacology 151:6, 779-786
CrossRef181
José A. Moro, Luis Almenar, Pilar Morales, Ana Osa. (2007) Efecto rebote tras la inhalación de prostaciclina en hipertensión pulmonar. Medicina Clínica 129:7, 279
CrossRef182
D. Dumitrescu, H. Freyhaus, K. Wasserman, S. Rosenkranz. (2007) Pulmonale Hypertonie. Der Pneumologe 4:4, 283-302
CrossRef183
Z. Daniil, E. Karetsi, E. Zakynthinos, E. Bakratsi, F. Kalala, K.I. Gourgoulianis. (2007) Pulmonary arterial hypertension in a patient with common variable immunodeficiency and unilateral bronchiectasis: Successful treatment with iloprost. European Journal of Internal Medicine 18:4, 333-335
CrossRef184
Birger Wolff, Sven Lodziewski, Tom Bollmann, Christian F. Opitz, Ralf Ewert. (2007) Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. American Heart Journal 153:6, 1088.e1-1088.e7
CrossRef185
Aniket Puri, Michael D McGoon, Sudhir S Kushwaha. (2007) Pulmonary arterial hypertension: current therapeutic strategies. Nature Clinical Practice Cardiovascular Medicine 4:6, 319-329
CrossRef186
Alejandro Macchia, Roberto Marchioli, RosaMaria Marfisi, Marco Scarano, Giacomo Levantesi, Luigi Tavazzi, Gianni Tognoni. (2007) A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal 153:6, 1037-1047
CrossRef187
Omar Ali, John Wharton, John Simon Russell Gibbs, Luke Howard, Martin Russell Wilkins. (2007) Emerging therapies for pulmonary arterial hypertension. Expert Opinion on Investigational Drugs 16:6, 803-818
CrossRef188
Lucy Waite, Rajan Madhok. (2007) Pulmonary hypertension in systemic sclerosis: a review of diagnostic and therapeutic options. Future Rheumatology 2:3, 279-286
CrossRef189
Horst Olschewski, M. M. Hoeper, M. M. Borst, R. Ewert, E. Grünig, F.-X. Kleber, B. Kopp, C. Opitz, F. Reichenberger, A. Schmeisser, D. Schranz, I. Schulze-Neick, H. Wilkens, J. Winkler, H. Worth. (2007) Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clinical Research in Cardiology 96:5, 301-330
CrossRef190
Isabel Otero González, Marina Blanco Aparicio, Ana Souto Alonso, Inés Raposo Sonnenfeld, Héctor Verea Hernando. (2007) Hipertensión pulmonar: eficacia clínica del sildenafilo en clases funcionales II-III. Archivos de Bronconeumología 43:5, 272-276
CrossRef191
Pavel Jansa, Michael Aschermann, David Ambroz, Ales Linhart. (2007) Pulmonary arterial hypertension – the challenge in diagnosis and treatment. Current Medical Research and Opinion 23:s2, S3-S9
CrossRef192
Christopher P. Denton, Svetlana I. Nihtyanova. (2007) Therapy of pulmonary arterial hypertension in systemic sclerosis: An update. Current Rheumatology Reports 9:2, 158-164
CrossRef193
Nazzareno Galiè, Naushad Hirani, Alessandra Manes, Serena Romanazzi, Massimiliano Palazzini, Luca Negro, Angelo Branzi. (2007) Long-term therapeutic outcomes in pulmonary arterial hypertension. Current Medical Research and Opinion 23:s2, S11-S18
CrossRef194
Raymond L. Benza, Myung H. Park, Anne Keogh, Reda E. Girgis. (2007) Management of Pulmonary Arterial Hypertension With a Focus on Combination Therapies. The Journal of Heart and Lung Transplantation 26:5, 437-446
CrossRef195
Anne V. LaRaia, Aaron B. Waxman. (2007) Pulmonary Arterial Hypertension: Evaluation and Management. Southern Medical Journal 100:4, 393-399
CrossRef196
Roger F. Johnson, James E. Loyd, Amy L. Mullican, Cynthia A. Fink, Ivan M. Robbins. (2007) Long-term Follow-up After Conversion from Intravenous Epoprostenol to Oral Therapy With Bosentan or Sildenafil in 13 Patients With Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 26:4, 363-369
CrossRef197
Inés Raposo-Sonnenfeld, Isabel Otero-González, Marina Blanco-Aparicio, Ángela Ferrer-Barba, Constancio Medrano-López. (2007) Tratamiento con sildenafilo y/o bosentán en niños y jóvenes con hipertensión arterial pulmonar idiopática y síndrome de Eisenmenger. Revista Española de Cardiología 60:4, 366-372
CrossRef198
Ségolène Cabrol, Rogerio Souza, Xavier Jais, Elie Fadel, Ratiba Haddad Si Ali, Marc Humbert, Philippe Dartevelle, Gérald Simonneau, Olivier Sitbon. (2007) Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. The Journal of Heart and Lung Transplantation 26:4, 357-362
CrossRef199
Ralf Ewert, Christian F. Opitz, Roland Wensel, Jörg Winkler, Michael Halank, Stephan B. Felix. (2007) Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clinical Research in Cardiology 96:4, 211-217
CrossRef200
S. Rosenkranz. (2007) Pulmonal arterielle Hypertonie. Clinical Research in Cardiology Supplements 2:2, 101-119
CrossRef201
Michael J. Landzberg. (2007) Congenital Heart Disease Associated Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 243-253
CrossRef202
Adolfo Baloira. (2007) Futuro del tratamiento de la hipertensión pulmonar. Archivos de Bronconeumología 43:3, 131-135
CrossRef203
Jeffrey S. Sager, Vivek N. Ahya. (2007) Surgical Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 187-202
CrossRef204
Wayne L. Strauss, Jeffrey D. Edelman. (2007) Prostanoid Therapy for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 127-142
CrossRef205
N. SKORO-SAJER, D. BONDERMAN, F. WIESBAUER, E. HARJA, J. JAKOWITSCH, W. KLEPETKO, M. P. KNEUSSL, I. M. LANG. (2007) Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis 5:3, 483-489
CrossRef206
Dermot O'Callaghan, Sean P. Gaine. (2007) Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 169-185
CrossRef207
F.-P. Tillmann, M. Jäger, D. Blondin, D. Schooldermann, A. Voiculescu, C. Sucker, B. Grabensee, R. Krauspe, G. R. Hetzel. (2007) Intravenous Iloprost: A New Therapeutic Option for Patients with Post-Transplant Distal Limb Syndrome (PTDLS). American Journal of Transplantation 7:3, 667-671
CrossRef208
Jennifer L. Snow, Steven M. Kawut. (2007) Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy. Clinics in Chest Medicine 28:1, 75-89
CrossRef209
Ana Oliveira, Daniela Ferreira, António Caiado, Susana Ferreira, Paula Ferreira, Lino Santos, Manuel Gonçalves, Teresa Shiang, Bárbara Parente, Rosas Vieira, Vasco Gama Ribeiro. (2007) Hipertensão arterial pulmonar – Experiência do Centro Hospitalar de Vila Nova de Gaia. Revista Portuguesa de Pneumologia (English Edition) 13:2, 239-254
CrossRef210
F. Reichenberger, A. Mainwood, N. Doughty, A. Fineberg, N.W. Morrell, J. Pepke-Zaba. (2007) Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respiratory Medicine 101:2, 217-222
CrossRef211
Herre J. Reesink, Mart N. van der Plas, Niesje E. Verhey, Reindert P. van Steenwijk, Jaap J. Kloek, Paul Bresser. (2007) Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. The Journal of Thoracic and Cardiovascular Surgery 133:2, 510-516
CrossRef212
BKS Sastry. (2007) Pharmacologic treatment for pulmonary arterial hypertension. Current Opinion in Internal Medicine 6:1, 11-18
CrossRef213
Rajiv Dhand. (2007) Inhalation therapy in invasive and noninvasive mechanical ventilation. Current Opinion in Critical Care 13:1, 27-38
CrossRef214
Anne M. Keogh, Keith D. McNeil, John Wlodarczyk, Eli Gabbay, Trevor J. Williams. (2007) Quality of Life in Pulmonary Arterial Hypertension: Improvement and Maintenance With Bosentan. The Journal of Heart and Lung Transplantation 26:2, 181-187
CrossRef215
S. Braun, H. Schrötter, A. Schmeisser, R.H. Strasser. (2007) Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. International Journal of Cardiology 115:1, 67-72
CrossRef216
H. Wilkens. (2007) Therapie der chronischen Thromboembolie (CTEPH). Der Pneumologe 4:1, 30-38
CrossRef217
2007. P. , 150-175.
CrossRef218
Gustavo A. Heresi, Omar A. Minai. (2007) Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy. Respiratory Medicine 101:10, 2099
CrossRef219
Neil A. Sheddan, Michael Czybowski, Johann Mulzer. (2007) Novel synthetic strategies for the preparation of prostacyclin and prostaglandin analogues ? off the beaten track. Chemical Communications:21, 2107
CrossRef220
E. Gabbay, A. Reed, T. J. Williams. (2007) Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. Internal Medicine Journal 37:1, 38-48
CrossRef221
Andrea Donti, Roberto Formigari, Luca Ragni, Alessandra Manes, Nazzareno Galiè, Fernando M Picchio. (2007) Pulmonary arterial hypertension in the pediatric age. Journal of Cardiovascular Medicine 8:1, 72-77
CrossRef222
Rajiv Dhand, Emmanuelle Mercier. (2007) Effective inhaled drug administration to mechanically ventilated patients. Expert Opinion on Drug Delivery 4:1, 47-61
CrossRef223
Derliz Mereles, Ralf Ewert, Sven Lodziewski, Mathias M. Borst, Andreas Benz, Horst Olschewski, Ekkehard Grünig. (2007) Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension. Respiration 74:5, 498-502
CrossRef224
Javier Segovia Cubero, Juan Camilo Ortiz Uribe, Manuel Gómez Bueno, Vanessa Moñivas Palomero, Magdalena González González, Luis Alonso-Pulpón Rivera. (2007) Efectividad del bosentán en el tratamiento de la hipertensión pulmonar debida a tromboembolia venosa crónica. Medicina Clínica 128:1, 12-14
CrossRef225
R. Souza, B. C. S. Martins, C. Jardim, F. Cortopassi, C. J. C. Fernandes, T. Pulido, J. Sandoval. (2007) Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. International Journal of Clinical Practice 61:1, 153-156
CrossRef226
Rogerio Souza, Carlos Jardim, Caio Julio Cesar Fernandes, Monica Silveira Lapa, Rogerio Rabelo, Marc Humbert. (2007) NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine 101:1, 69-75
CrossRef227
David Sidebotham. 2007. Pulmonary Hypertension. , 374-382.
CrossRef228
Robyn J Barst. (2007) Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 8:1, 95
CrossRef229
Marius M. Hoeper, Stephen H. Lee, Robert Voswinckel, Massimiliano Palazzini, Xavier Jais, Alessandro Marinelli, Robyn J. Barst, Hossein A. Ghofrani, Zhi-Cheng Jing, Christian Opitz, Hans-Juergen Seyfarth, Michael Halank, Vallerie McLaughlin, Ronald J. Oudiz, Ralf Ewert, Heinrike Wilkens, Stefan Kluge, Hinrich-Cordt Bremer, Eva Baroke, Lewis J. Rubin. (2006) Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology 48:12, 2546-2552
CrossRef230
M. Flondor, M. Merkel, C. Hofstetter, M. Irlbeck, L. Frey, B. Zwissler. (2006) The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy. Anaesthesia 61:12, 1200-1203
CrossRef231
S. Alp, M. Skrygan, W.E. Schmidt, A. Bastian. (2006) Sildenafil improves hemodynamic parameters in COPD—an investigation of six patients. Pulmonary Pharmacology & Therapeutics 19:6, 386-390
CrossRef232
Erika B Rosenzweig. (2006) Emerging treatments for pulmonary arterial hypertension. Expert Opinion on Emerging Drugs 11:4, 609-619
CrossRef233
E. Vázquez Muñoz, J.J. Vázquez Rodríguez. (2006) Hipertensión pulmonar. Medicine - Programa de Formación Médica Continuada Acreditado 9:66, 4241-4247
CrossRef234
Teresa De Marco. (2006) Pulmonary Arterial Hypertension and Women. Cardiology in Review 14:6, 312-318
CrossRef235
2006. Pulmonary Hypertension. .
CrossRef236
Richard N. Channick, Horst Olschewski, Werner Seeger, Ted Staub, Robert Voswinckel, Lewis J. Rubin. (2006) Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 48:7, 1433-1437
CrossRef237
Stephen L Archer, Evangelos D Michelakis. (2006) An evidence-based approach to the management of pulmonary arterial hypertension. Current Opinion in Internal Medicine 5:5, 453-460
CrossRef238
Makoto Sahara, Toshiyuki Takahashi, Yasushi Imai, Toshiaki Nakajima, Atsushi Yao, Toshihiro Morita, Yasunobu Hirata, Ryozo Nagai. (2006) New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs and Therapy 20:5, 377-386
CrossRef239
Robert Voswinckel, Beate Enke, Frank Reichenberger, Markus Kohstall, Andree Kreckel, Stefanie Krick, Henning Gall, Tobias Gessler, Thomas Schmehl, Hossein A. Ghofrani, Ralph Theo Schermuly, Friedrich Grimminger, Lewis J. Rubin, Werner Seeger, Horst Olschewski. (2006) Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology 48:8, 1672-1681
CrossRef240
K. Valchanov, A. Vuylsteke. (2006) Pulmonary endarterectomy. European Journal of Anaesthesiology 23:10, 815-823
CrossRef241
K. Lunze, N. Gilbert, S. Mebus, O. Miera, W. Fehske, F. Uhlemann, E. G. Muhler, P. Ewert, P. E. Lange, F. Berger, I. Schulze-Neick. (2006) First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. European Journal of Clinical Investigation 36:s3, 32-38
CrossRef242
Ralph Theo Schermuly, Andreas Schulz, Hossein Ardeschir Ghofrani, Christina Susanne Breitenbach, Norbert Weissmann, Michael Hildebrand, Julia Kurz, Friedrich Grimminger, Werner Seeger. (2006) Comparison of Pharmacokinetics and Vasodilatory Effect of Nebulized and Infused Iloprost in Experimental Pulmonary Hypertension: Rapid Tolerance Development. Journal of Aerosol Medicine 19:3, 353-363
CrossRef243
F. Cozzi, R. Montisci, H. Marotta, F. Bobbo, N. Durigon, M. Ruscazio, P. Sfriso, S. Iliceto, S. Todesco. (2006) Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. European Journal of Clinical Investigation 36:s3, 49-53
CrossRef244
Sabina A Antoniu. (2006) Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opinion on Pharmacotherapy 7:13, 1801-1810
CrossRef245
Lorinda Chung, Jan Lin, Daniel E. Furst, David Fiorentino. (2006) Systemic and localized scleroderma. Clinics in Dermatology 24:5, 374-392
CrossRef246
M. Beghetti. (2006) Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. European Journal of Clinical Investigation 36:s3, 16-24
CrossRef247
Hossein A. Ghofrani, Ian H. Osterloh, Friedrich Grimminger. (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery 5:8, 689-702
CrossRef248
Yannick Allanore, André Kahan. (2006) Treatment of systemic sclerosis. Joint Bone Spine 73:4, 363-368
CrossRef249
F. H. J. Hoogen. (2006) Behandlung der systemischen Sklerose. Zeitschrift für Rheumatologie 65:4, 306-310
CrossRef250
K. Ahmadi-Simab, W. L. Gross. (2006) Pulmonale arterielle Hypertonie bei Kollagenosen: Klinik, Epidemiologie, Pathogenese, Diagnostik und Therapie. Zeitschrift für Rheumatologie 65:4, 297-305
CrossRef251
Martin Beiderlinden, Hilmar Kuehl, Tanja Boes, Jürgen Peters. (2006) Prevalence of pulmonary hypertension associated with severe acute respiratory distress syndrome: Predictive value of computed tomography. Intensive Care Medicine 32:6, 852-857
CrossRef252
Srinivas Murali. (2006) Pulmonary arterial hypertension. Current Opinion in Critical Care 12:3, 228-234
CrossRef253
Chao Liu, Kunshen Liu, Zhenguo Ji, Gang Liu. (2006) Treatments for pulmonary arterial hypertension. Respiratory Medicine 100:5, 765-774
CrossRef254
D. S. O'Callaghan, S. P. Gaine. (2006) Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. International Journal of Clinical Practice 60:4, 475-481
CrossRef255
&NA;. (2006) Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension. Drugs & Therapy Perspectives 22:4, 11-15
CrossRef256
Sabina A Antoniu. (2006) Sildenafil citrate for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 7:6, 825-828
CrossRef257
Hideaki Uchiyama, Yuji Soejima, Akinobu Taketomi, Tomoharu Yoshizumi, Noboru Harada, Hideki Ijichi, Yusuke Yonemura, Yoshihiko Maehara. (2006) Successful adult-to-adult living donor liver transplantation in a patient with moderate to severe portopulmonary hypertension. Liver Transplantation 12:3, 481-484
CrossRef258
Janet E. Pope, Janine M. Ouimet, Adriana Krizova. (2006) Scleroderma treatment differs between experts and general rheumatologists. Arthritis & Rheumatism 55:1, 138-145
CrossRef259
S. P. McKenna, N. Doughty, D. M. Meads, L. C. Doward, J. Pepke-Zaba. (2006) The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension. Quality of Life Research 15:1, 103-115
CrossRef260
Reem M. Haj, J. Erric Cinco, C. David Mazer. (2006) Treatment of pulmonary hypertension with selective pulmonary vasodilators. Current Opinion in Anaesthesiology 19:1, 88-95
CrossRef261
Y. Allanore, A. Kahan. (2006) Traitement de la sclérodermie systémique. Annales de Dermatologie et de Vénéréologie 133:3, 286
CrossRef262
Erika Berman Rosenzweig, Robyn J Barst. (2006) Pulmonary Arterial Hypertension. Treatments in Respiratory Medicine 5:2, 117-127
CrossRef263
Sherri L. Katz, Ian Adatia, Emily Louca, Kitty Leung, T. Humpl, Janette T. Reyes, Allan L. Coates. (2006) Nebulized therapies for childhood pulmonary hypertension: An in vitro model. Pediatric Pulmonology 41:7, 666
CrossRef264
B. Rosengarten, R.T. Schermuly, R. Voswinckel, M.G. Kohstall, H. Olschewski, N. Weissmann, W. Seeger, M. Kaps, F. Grimminger, H.A. Ghofrani. (2006) Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. Cerebrovascular Diseases 21:3, 194-200
CrossRef265
Jeffrey C Horowitz, Victor J Thannickal. (2006) Idiopathic Pulmonary Fibrosis. Treatments in Respiratory Medicine 5:5, 325-342
CrossRef266
Christine Archer-Chicko, Traci Housten-Harris, Harold I. Palevsky. 2006. Practical Nursing Issues in the Outpatient Management of Pulmonary Vascular Disease. , 314-329.
CrossRef267
Hye Sook Choi, Sang Do Lee. (2006) Medeical Therapy For Pulmonary Arterial Hypertention. Tuberculosis and Respiratory Diseases 60:2, 142
CrossRef268
Azad Raiesdana, Joseph Loscalzo. (2006) Pulmonary arterial hypertension. Annals of Medicine 38:2, 95-110
CrossRef269
Kelly M. Chin, Peter F. Fedullo. 2006. Chronic Thromboembolic Pulmonary Hypertension. , 188-209.
CrossRef270
Asrar Rashid, D. Dunbar Ivy. 2006. Pulmonary Hypertension in Children. , 274-287.
CrossRef271
Kevin B. MARTIN, James R. KLINGER, Sharon I. S. ROUNDS. (2006) Pulmonary arterial hypertension: New insights and new hope. Respirology 11:1, 6-17
CrossRef272
Steven H. Abman. (2006) Pulmonary hypertension in older children: New approaches and therapies. Paediatric Respiratory Reviews 7, S177-S179
CrossRef273
Kang Hyeon Choe. (2006) Complications of Chronic Obstructive Pulmonary Disease. Journal of the Korean Medical Association 49:4, 321
CrossRef274
Anna M. Hackman, Thomas E. Lackner. (2006) Pharmacotherapy for Idiopathic Pulmonary Arterial Hypertension During the Past 25 Years. Pharmacotherapy 26:1, 68-94
CrossRef275
Jess Mandel. 2006. Treatment for Pulmonary Arterial Hypertension. , 99-118.
CrossRef276
Carmine Dario Vizza, Roberto Badagliacca, Susanna Sciomer, Roberto Poscia, Alessandro Battagliese, Mauro Schina, Luciano Agati, Francesco Fedele. (2006) Mid-Term Efficacy of Beraprost, an Oral Prostacyclin Analog, in the Treatment of Distal CTEPH: A Case Control Study. Cardiology 106:3, 168-173
CrossRef277
P. Diot,, P. Magro, L. Vecellio, G.C. Smaldone. (2006) Advances in Our Understanding of Aerosolized Iloprost for Pulmonary Hypertension. Journal of Aerosol Medicine 19:3, 406
CrossRef278
Griffiths, Mark J.D., Evans, Timothy W., . (2005) Inhaled Nitric Oxide Therapy in Adults. New England Journal of Medicine 353:25, 2683-2695
Full Text279
Hai Wang, Yuan Tang, Ying-Li Zhang. (2005) Hypoxic Pulmonary Hypertension (HPH) and Iptakalim, a Novel ATP-sensitive Potassium Channel Opener Targeting Smaller Arteries in Hypertension. Cardiovascular Drug Reviews 23:4, 293-316
CrossRef280
Galiè, Nazzareno, Ghofrani, Hossein A., Torbicki, Adam, Barst, Robyn J., Rubin, Lewis J., Badesch, David, Fleming, Thomas, Parpia, Tamiza, Burgess, Gary, Branzi, Angelo, Grimminger, Friedrich, Kurzyna, Marcin, Simonneau, Gérald, . (2005) Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine 353:20, 2148-2157
Full Text281
H. Schotte, H. Becker, W. Domschke, M. Gaubitz. (2005) Kardiovaskuläres Monitoring von Patienten mit systemischem Lupus erythematodes. Zeitschrift für Rheumatologie 64:8, 564-575
CrossRef282
Darleen R. Powars, Linda S. Chan, Alan Hiti, Emily Ramicone, Cage Johnson. (2005) Outcome of Sickle Cell Anemia. Medicine 84:6, 363-376
CrossRef283
Kaan Okyay, Mustafa Cemri, Bulent Boyac, Rdvan Yalcn, Atiye Cengel. (2005) Use of Long-Term Combined Therapy With Inhaled Iloprost and Oral Sildenafil in an Adult Patient With Eisenmenger Syndrome. Cardiology in Review 13:6, 312-314
CrossRef284
GIORGIO DERCHI, GIAN LUCA FORNI. (2005) Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies: Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Annals of the New York Academy of Sciences 1054:1, 471-475
CrossRef285
Ghofrani, Hossein A., Seeger, Werner, Grimminger, Friedrich, . (2005) Imatinib for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine 353:13, 1412-1413
Full Text286
Saima Muzaffar, Nilima Shukla, Amit Srivastava, Gianni D Angelini, Jamie Y Jeremy. (2005) Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91 phox expression in porcine pulmonary artery endothelial cells. British Journal of Pharmacology 146:1, 109-117
CrossRef287
Nick H. S. Kim, Lewis J. Rubin. (2005) Management following pulmonary thromboendarterectomy: Experience versus evidence*. Critical Care Medicine 33:9, 2132-2133
CrossRef288
S. H. LEE, L. J. RUBIN. (2005) Current treatment strategies for pulmonary arterial hypertension. Journal of Internal Medicine 258:3, 199-215
CrossRef289
Henry H Hsu, Lewis J Rubin. (2005) Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 6:11, 1921-1930
CrossRef290
J.M. Borro. (2005) Actualización del trasplante pulmonar en España. Archivos de Bronconeumología 41:8, 457-467
CrossRef291
Peter Germann, Antonio Braschi, Giorgio Della Rocca, Anh Tuan Dinh-Xuan, Konrad Falke, Claes Frostell, Lars E. Gustafsson, Philippe Hervé, Philippe Jolliet, Udo Kaisers, Hector Litvan, Duncan J. Macrae, Marco Maggiorini, Nandor Marczin, Bernd Mueller, Didier Payen, Marco Ranucci, Dietmar Schranz, Rainer Zimmermann, Roman Ullrich. (2005) Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Medicine 31:8, 1029-1041
CrossRef292
Steeve Provencher, Olivier Sitbon, Gérald Simonneau. (2005) Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opinion on Pharmacotherapy 6:8, 1337-1348
CrossRef293
O. Eickelberg, W. Seeger. (2005) Pulmonale Hypertonie. Der Internist 46:7, 759-768
CrossRef294
Lewis J Rubin, Christopher Dufton, Michael J Gerber. (2005) Ambrisentan for pulmonary arterial hypertension. Future Cardiology 1:4, 425-432
CrossRef295
Erika Berman Rosenzweig, Robyn J Barst. (2005) Idiopathic pulmonary arterial hypertension in children. Current Opinion in Pediatrics 17:3, 372-380
CrossRef296
Adaani E. Frost, D. Langleben, R. Oudiz, N. Hill, E. Horn, V. McLaughlin, I.M. Robbins, S. Shapiro, V.F. Tapson, D. Zwicke, T. DeMarco, R. Schilz, M. Rubenfire, R.J. Barst. (2005) The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect. Vascular Pharmacology 43:1, 36-39
CrossRef297
E. Czeslick, T. Hentschel, I. Friedrich, S. Grond, A. Sablotzki. (2005) Inhalative Vasodilatatoren in der kardiochirurgischen Intensivmedizin. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 19:3, 132-145
CrossRef298
Beatriz Bouzas, Michael A. Gatzoulis. (2005) Hipertensión arterial pulmonar en adultos con cardiopatía congénita. Revista Española de Cardiología 58:5, 465-469
CrossRef299
Petros Perimenis. (2005) Sildenafil for the treatment of altitude-induced hypoxaemia. Expert Opinion on Pharmacotherapy 6:5, 835-837
CrossRef300
Steeve Provencher, Xavier Jais, Olivier Sitbon. (2005) Bosentan therapy for pulmonary arterial hypertension. Future Cardiology 1:3, 299-309
CrossRef301
(2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. Revista Española de Cardiología 58:5, 523-566
CrossRef302
Friedrich M. Fruhwald, Barbro Kjellström, Wolfgang Perthold, Manfred Wonisch, Robert Maier, Werner Klein. (2005) Hemodynamic Observations in Two Pulmonary Hypertensive Patients Changing Treatment From Inhaled Iloprost to the Oral Endothelin-Antagonist Bosentan. The Journal of Heart and Lung Transplantation 24:5, 631-634
CrossRef303
N Shanthi Paramothayan, Toby J Lasserson, Athol Wells, E. Haydn Walters, N Shanthi Paramothayan. 2005. Prostacyclin for pulmonary hypertension in adults. .
CrossRef304
M. Dandel, R. Hetzer. (2005) Chirurgische Aspekte des pulmonalen Hochdrucks. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 19:2, 57-74
CrossRef305
Hanno H Leuchte, Jürgen Behr. (2005) Iloprost for idiopathic pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy 3:2, 215-223
CrossRef306
H. Olschewski, A. Ghofrani, B. Enke, F. Reichenberger, R. Voswinckel, A. Kreckel, S. Ghofrani, R. Wiedemann, R. Schulz, F. Grimminger, W. Seeger. (2005) Medikament
se Therapie der pulmonalen Hypertonie. Der Internist 46:3, 341-349
CrossRef307
Roxana Sulica, Michael Poon. (2005) Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine. Expert Review of Cardiovascular Therapy 3:2, 347-360
CrossRef308
G. Riemekasten, H. Schulze-Koops. (2005) Medikament
CrossRef309
Masakuni Kido, Lingling Du, Christopher C. Sullivan, Reena Deutsch, Stuart W. Jamieson, Patricia A. Thistlethwaite. (2005) Gene transfer of a TIE2 receptor antagonist prevents pulmonary hypertension in rodents. The Journal of Thoracic and Cardiovascular Surgery 129:2, 268-276
CrossRef310
Roland Demeyere, Marion Delcroix, Willem Daenen. (2005) Anaesthesia management for pulmonary endarterectomy. Current Opinion in Anaesthesiology 18:1, 63-76
CrossRef311
G. Kemming, H. Kisch-Wedel, M. Flondor, C. Hofstetter, W. Kreyling, E. Thein, F. Meisner, S. Bruhn, B. Zwissler. (2005) Improved Ventricular Function during Inhalation of PGI<sub>2</sub> Aerosol Partly Relies on Enhanced Myocardial Contractility. European Surgical Research 37:1, 9-17
CrossRef312
Michael Dandel, Hans B. Lehmkuhl, Roland Hetzer. (2005) Advances in the Medical Treatment of Pulmonary Hypertension. Kidney and Blood Pressure Research 28:5-6, 311-324
CrossRef313
Kenya Saji, Masahito Sakuma, Jun Suzuki, Tohru Takahashi, Jun Demachi, Jun Nawata, Osamu Kitamukai, Noriko Onoue, Kouichiro Sugimura, Tomohiro Tada, Shigefumi Fukui, Yutaka Kagaya, Jun Watanabe, Kunio Shirato. (2005) Efficacy of Acute Inhalation of Nitric Oxide in Patients With Primary Pulmonary Hypertension Using Chronic Use of Continuous Epoprostenol Infusion. Circulation Journal 69:3, 335-338
CrossRef314
Mehmet C. Oz, Abbas Ardehali. (2004) Collective Review: Perioperative Uses of Inhaled Nitric Oxide in Adults. The Heart Surgery Forum 7:6, E584-E589
CrossRef315
H. Olschewski. (2004) Therapie der pulmonalen Hypertonie. Der Pneumologe 1:2, 95-101
CrossRef316
J Denyer, K Nikander, N J Smith. (2004) Adaptive Aerosol Delivery (AAD ® ) technology. Expert Opinion on Drug Delivery 1:1, 165-176
CrossRef317
H. Golpon, M. M. Hoeper, T. Welte. (2004) Klassifikation der pulmonalen Hypertonie. Der Pneumologe 1:2, 77-82
CrossRef318
Hossein A. Ghofrani, Robert Voswinckel, Frank Reichenberger, Horst Olschewski, Peter Haredza, Burcu Karadaş, Ralph T. Schermuly, Norbert Weissmann, Werner Seeger, Friedrich Grimminger. (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology 44:7, 1488-1496
CrossRef319
D. Montani, X. Jaïs, V. Ioos, O. Sitbon, G. Simonneau, M. Humbert. (2004) Traitement de l'hypertension artérielle pulmonaire. La Revue de Médecine Interne 25:10, 720-731
CrossRef320
Anne Keogh, John Wlodarczyk. (2004) Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QOL on bosentan. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, 505-513
CrossRef321
R COHEN, A TALWAR, L EFFEREN. (2004) Exacerbation of underlying pulmonary disease in pregnancy. Critical Care Clinics 20:4, 713-730
CrossRef322
Humbert, Marc, Sitbon, Olivier, Simonneau, Gérald, . (2004) Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine 351:14, 1425-1436
Full Text323
Pierre Tissières, Laurent Nicod, Constance Barazzone-Argiroffo, Peter C. Rimensberger, Maurice Beghetti. (2004) Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. The Annals of Thoracic Surgery 78:3, e48-e50
CrossRef324
Irene M Lang, Diana Bonderman, Meinhard Kneussl, Manfred Marx. (2004) Paediatric pulmonary vascular disease. Paediatric Respiratory Reviews 5:3, 238-248
CrossRef325
Yolanda Braun-Moscovici, A.Menahem Nahir, Alexandra Balbir-Gurman. (2004) Endothelin and pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism 34:1, 442-453
CrossRef326
MICHAEL ANDREAS KANDLER, KATHARINA VON DER HARDT, NELLY GERICKE, MARTIN CHADA, J??RG D??TSCH, WOLFGANG RASCHER. (2004) Dose Response to Aerosolized Perflubron in a Neonatal Swine Model of Lung Injury. Pediatric Research 56:2, 191-197
CrossRef327
Erika Berman Rosenzweig, Allison C. Widlitz, Robyn J. Barst. (2004) Pulmonary arterial hypertension in children. Pediatric Pulmonology 38:1, 2-22
CrossRef328
Angela T Zimmerman, Laura M Ibsen. (2004) Advances in postoperative care of pediatric cardiac patients. Current Opinion in Anaesthesiology 17:3, 241-246
CrossRef329
M. Mueller, C. Neuhaeuser, R. Noest, H. Akintuerk, I. Welters, G. Hempelmann. (2004) Inhaled iloprost in the management of pulmonary hypertension in infants undergoing congenital heart surgery. European Journal of Anaesthesiology 21:Supplement 33, 3
CrossRef330
S. Müller-Späth, S. Schroth, S. Rex, T. Busch, R. Rossaint, W. Buhre. (2004) Iloprost: a positive inotropic effect in isolated myocardium?. European Journal of Anaesthesiology 21:Supplement 33, 33
CrossRef331
Nazzareno Galiè, Werner Seeger, Robert Naeije, Gerald Simonneau, Lewis J. Rubin. (2004) Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S81-S88
CrossRef332
Lewis J Rubin, Nazzareno Galiè. (2004) Pulmonary arterial hypertension: a look to the future. Journal of the American College of Cardiology 43:12, S89-S90
CrossRef333
Gerald Simonneau, Nazzareno Galiè, Lewis J Rubin, David Langleben, Werner Seeger, Guido Domenighetti, Simon Gibbs, Didier Lebrec, Rudolf Speich, Maurice Beghetti, Stuart Rich, Alfred Fishman. (2004) Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 43:12, S5-S12
CrossRef334
Marius M Hoeper, Ronald J Oudiz, Andrew Peacock, Victor F Tapson, Sheila G Haworth, Adaani E Frost, Adam Torbicki. (2004) End points and clinical trial designs in pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S48-S55
CrossRef335
Hossein A Ghofrani, Joanna Pepke-Zaba, Joan A Barbera, Richard Channick, Anne M Keogh, Miguel A Gomez-Sanchez, Meinhard Kneussl, Friedrich Grimminger. (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S68-S72
CrossRef336
David B Badesch, Vallerie V McLaughlin, Marion Delcroix, CarmineDario Vizza, Horst Olschewski, Olivier Sitbon, Robyn J Barst. (2004) Prostanoid therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S56-S61
CrossRef337
Marius M Hoeper, Michael J Krowka, Christian P Strassburg. (2004) Portopulmonary hypertension and hepatopulmonary syndrome. The Lancet 363:9419, 1461-1468
CrossRef338
Horst Olschewski, Frank Rose, Ralph Schermuly, H.Ardeschir Ghofrani, Beate Enke, Andrea Olschewski, Werner Seeger. (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 102:2, 139-153
CrossRef339
Susan Steinbis. (2004) What You Should Know About Pulmonary Hypertension. The Nurse Practitioner 29:4, 8-19
CrossRef340
Jean-Luc Vachiéry, Robert Naeije. (2004) Treprostinil for pulmonary hypertension. Expert Review of Cardiovascular Therapy 2:2, 183-191
CrossRef341
Tim Higenbottam, Liz Laude, Celia Emery, Mohamed Essener. (2004) Pulmonary hypertension as a result of drug therapy. Clinics in Chest Medicine 25:1, 123-131
CrossRef342
Hanno H. Leuchte, Michael Holzapfel, Rainer A. Baumgartner, Isabelle Ding, Claus Neurohr, Michael Vogeser, Tilman Kolbe, Martin Schwaiblmair, Jürgen Behr. (2004) Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. Journal of the American College of Cardiology 43:5, 764-770
CrossRef343
E Hachulla. (2004) Traitement de l’hypertension artérielle pulmonaire associée à la sclérodermie systémique. La Revue de Médecine Interne 25:3, 195-200
CrossRef344
Kelly Chin, Richard Channick. (2004) Bosentan. Expert Review of Cardiovascular Therapy 2:2, 175-182
CrossRef345
Marius M Hoeper, Ronald J Oudiz, Andrew Peacock, Victor F Tapson, Sheila G Haworth, Adaani E Frost, Adam Torbicki. (2004) End points and clinical trial designs in pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S48
CrossRef346
B.K.S. Sastry, C. Narasimhan, N.Krishna Reddy, B.Soma Raju. (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension. Journal of the American College of Cardiology 43:7, 1149
CrossRef347
David R Goldsmith, Antona J Wagstaff. (2004) Inhaled Iloprost. Drugs 64:7, 763-773
CrossRef348
H. Erhan Dincer, Kenneth W. Presberg. (2004) Current Management of Pulmonary Hypertension. Clinical Pulmonary Medicine 11:1, 40-53
CrossRef349
Hirahito ENDO, Sumiaki TANAKA, Miho SAKAI. (2004) Japanese Journal of Clinical Immunology 27:3, 127-136
CrossRef350
Steffen Rex, Thomas Busch, Manfred Vettelschoss, Lothar de Rossi, Rolf Rossaint, Wolfgang Buhre. (2003) Intraoperative Management of Severe Pulmonary Hypertension during Cardiac Surgery with Inhaled Iloprost. Anesthesiology 99:3, 745-747
CrossRef351
Thorsten Kramm, Balthasar Eberle, Frank Krummenauer, Stefan Guth, Hellmut Oelert, Eckhard Mayer. (2003) Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. The Annals of Thoracic Surgery 76:3, 711-718
CrossRef352
Kathleen Srock, Leslie Dubin Kerr, Michael Poon, John T. Fallon. (2003) Refractory Pulmonary Hypertension in a Lupus Patient with Occult Pulmonary Vasculitis. JCR: Journal of Clinical Rheumatology 9:4, 263-266
CrossRef353
Serap Alp, Renate Schlottmann, Torsten T Bauer, Wolfgang E Schmidt, Andreas Bastian. (2003) Long-time survival with HIV-related pulmonary arterial hypertension. AIDS 17:11, 1714-1715
CrossRef354
Peter N Kao, John L Faul. (2003) Emerging therapies for pulmonary hypertension. Journal of the American College of Cardiology 41:12, 2126-2129
CrossRef355
Simon C. Hillier. (2003) Recent advances in the treatment of pulmonary hypertension. Current Opinion in Anaesthesiology 16:3, 331-336
CrossRef356
Christopher P Denton, Carol M Black. (2003) Pulmonary hypertension in systemic sclerosis. Rheumatic Disease Clinics of North America 29:2, 335-349
CrossRef357
Rolf Ziesche. (2003) Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose. Wiener Klinische Wochenschrift 115:10, 351-365
CrossRef358
James R Runo, James E Loyd. (2003) Primary pulmonary hypertension. The Lancet 361:9368, 1533-1544
CrossRef359
Udo Kaisers, Thilo Busch, Maria Deja, Bernd Donaubauer, Konrad J. Falke. (2003) Selective pulmonary vasodilation in acute respiratory distress syndrome. Critical Care Medicine 31:Supplement, S337-S342
CrossRef360
James P. Maloney. (2003) Advances in the treatment of secondary pulmonary hypertension. Current Opinion in Pulmonary Medicine 9:2, 139-143
CrossRef361
Kenneth W. Presberg, H. Erhan Dincer. (2003) Pathophysiology of pulmonary hypertension due to lung disease. Current Opinion in Pulmonary Medicine 9:2, 131-138
CrossRef362
Rolf Dembinski, Rolf Rossaint, Ralf Kuhlen. (2003) Modulating the pulmonary circulation: an update. Current Opinion in Anaesthesiology 16:1, 59-64
CrossRef363
Hossein A Ghofrani, Frank Rose, Ralph T Schermuly, Horst Olschewski, Ralph Wiedemann, André Kreckel, Norbert Weissmann, Stefanie Ghofrani, Beate Enke, Werner Seeger, Friedrich Grimminger. (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology 42:1, 158
CrossRef364
John Varga. (2002) Pulmonary hypertension in systemic sclerosis: bete noire no more?. Current Opinion in Rheumatology 14:6, 666-670
CrossRef365
Lionel Schachna, Fredrick M. Wigley. (2002) Targeting mediators of vascular injury in scleroderma. Current Opinion in Rheumatology 14:6, 686-693
CrossRef366
NS Paramothayan, TJ Lasserson, AU Wells, EH Walters. 2002. Prostacyclin for pulmonary hypertension in adults. .
CrossRef
